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GENERAL INTRODUCTION 
Margareta Nilson 
The mandate of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), as set out in its founding Regulation, is to collect, analyse and disseminate 
objective, reliable and comparable information on drugs and drug addiction in the 
European Union (EU).1 One of the EMCDDA's primary areas of focus is the demand 
for drugs and reducing that demand. 
Treating drug addiction is one of the main pillars of drug demand reduction. In all 
15 EU Member States, specific treatment systems have developed over the last few 
decades. In recent years, moreover, many of these systems have been revised and 
diversified, largely in response to the spread of HIV and AIDS and to increasing 
financial restraints in the public sector. 
Knowledge about the actual effects of treatment - what works - has not, however, 
always kept pace with these developments. As a result, it is essential to develop and 
disseminate high-quality information about appropriate methods, instruments and 
indicators to enhance the comprehensive evaluation of treatment programmes for 
drug users, as well as to allow for comparative evaluation of different programmes. 
Such knowledge not only enables policy-makers to make informed and appropriate 
decisions, but also increases the quality of the work carried out by all those involved 
in the drugs field. Furthermore, high-quality information can only be obtained from 
evaluated treatments. 
The EMCDDA is, therefore, focusing on promoting the evaluation of drug treatment 
and disseminating this information to policy-makers and professionals throughout 
Europe. 
The starting point for this work was the EMCDDA 'Workshop on the Evaluation of 
Drug Abuse Treatment', held in Athens from 17-18 March 1997. The main aims of 
this meeting were: 
• to function as a forum for exchanging ideas and experiences; 
• to define the EMCDDA's mid-term Work Programme in the field of treatment 
evaluation; and 
• to raise the profile of the EMCDDA within the relevant scientific community in 
Europe. 
The participants were asked to tackle priority issues in treatment evaluation, such as 
the conceptual frameworks of evaluation and treatment, and the aims of assessing 
treatment. Methodologies and implementation were also targeted, as were ways of 
1 European Council Regulation (EEC) no. 302/93, 8 February 1993. 
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making evaluation information more relevant to professionals and decision-makers 
and promoting communication between all those involved. 
The workshop was attended by experts from Germany, Greece, Italy, the 
Netherlands, Sweden and the United Kingdom. The COST-A6 working group on 
evaluating treatment and the World Health Organisation (WHO)'s Programme on 
Substance Abuse were also represented.2 The two-day meeting began by examining 
the main areas of treatment evaluation. This was followed by a debate, and recom-
mendations for further action were then made to the EMCDDA. 
This monograph is made up of the papers presented at the workshop, and is divided 
into three sections: 
• the theory of treatment evaluation; 
• the practice of treatment evaluation; and 
• the policy of treatment evaluation. 
These sections are followed by a workshop summary, a list of the recommendations 
made to the EMCDDA for its mid-term work plan on treatment evaluation and latest 
perspectives on the Centre's work in this field. 
2 COST A-6 is a programme run by the European Commission's Directorate General XII (Science, 
Research, Development) to gain valid information concerning the impact of various drug policies and 
measures on the extent, nature and consequences of drug abuse. 
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n Chapter 7, Vincent Hendriks looks at the current state of treatment evalua­
tion. He argues that evaluators, researchers and practitioners are still faced with 
the same questions as 20 or 30 years ago, including: does treatment work? 
What constitutes 'treatment' and 'success'? What are the 'active ingredients' of treat­
ment? And what treatment works for which client? Hendriks goes on to explore the 
difficult research issue of randomisation and seeks a way through the ethical tangle 
by discussing 'client, treatment and process'. 
Chapter 2, by Petra Paula Merino of the EMCDDA, presents an overview of the 
treatment-evaluation literature, highlighting prominent themes and dilemmas 
including the non-comparability of research findings and the problems of defining 
effectiveness. Merino discusses how few investigations specifically examine the way 
staffing and working conditions relate to the effectiveness of treatment and how the 
study of treatment has often been divorced from that of the drug user. 
In Chapter 3, Mats Fridell examines some of the most complex areas in the evalua­
tion of residential treatment. He demonstrates that an array of different research 
approaches must be considered, depending on whether the aim is to study effects, 
outcome or quality. No single research design provides the answers to all these 
fields, and many - if not most - of the problems related to institutional treatment 
might be better approached by models other than the traditional randomised control 
study. 
Chapter 4 examines the methodological aspects of evaluation in greater detail, in par­
ticular the randomised control study itself. While arguing that such studies provide 
the best chance for valid evaluation, Fabio Mariani identifies a number of issues 
which make randomised controls difficult in reality. One of these problems is the low 
level of statistical and epidemiological competence among drug professionals, 
and he calls on the EMCDDA to encourage greater knowledge of such matters. 
In Chapter 5, Evi Hatziandreou introduces and defines the contemporary issue of 
economic evaluation - a form of research that identifies, measures, values and 
compares the costs and benefits of different approaches to treatment. As such, she 
argues, economic evaluation deals explicitly with choices by examining the conse­
quences of any intervention under consideration. Hatziandreou outlines economic 
evaluation methods, presents the results of such techniques and recommends ways 
of realising the full potential of this form of assessment. 
1 ι 
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CHAPTER 1 
EVALUATING DRUG-ABUSE TREATMENT: 
CURRENT AND FUTURE PERSPECTIVES 
Vincent Hendriks 
Over the past three decades, an enormous amount of research has been conducted 
on evaluating the treatment of addiction. Evaluation studies range from the large-
scale US Drug Abuse Reporting Program (DARP) and Treatment Outcome 
Prospective Study (TOPS) initiatives of the 1960s and 1970s, and the current 
National Treatment Outcome Research Study (NTORS) in the UK, to numerous 
smaller-scale clinical investigations, often at individual programme level. 
Despite these considerable efforts, addiction-treatment researchers in the 1990s -
and into the next millennium - are and still wil l be confronted with very much the 
same core questions as those of 20 or 30 years ago. These questions include: 
• Does treatment work and what constitutes 'treatment' and 'success'? 
• How does treatment work and what are its active ingredients? 
• What kind of treatment works for what kind of client? 
This chapter provides some answers to these perennial and fundamental questions. 
Does treatment work and what constitutes 'treatment' and 'success'? 
Many studies have indicated that treatment 'works' for a considerable number of 
clients. Roughly speaking, the 'rule of thirds' (Miller and Sanchez-Craig, 1996) 
seems to apply to treatment outcome for both alcoholism and illicit drug use: about 
one-third of clients become abstinent; one-third improve, but are not abstinent; and 
one-third do not improve following treatment. 
While there is cumulative evidence that treatment does 'work', it is also clear that 
most of that evidence comes from naturalistic studies that have used a wide variety of 
methods to evaluate treatment outcome. Just how easy it is for different approaches 
to lead to different results is shown by Miller and Sanchez-Craig (1996), who gave 
the following advice to treatment programmes faced with increasing pressure from 
funders to show high success rates: 
• choose only cases with good prognoses to evaluate; 
• keep follow-up periods as short as possible; 
13 
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• avoid control or comparison groups; 
• choose outcome measures carefully; 
• focus only on alcohol or drug variables; 
• use liberal definitions of success; 
• rely exclusively on self-report; and 
• always declare victory, regardless of the findings! 
Ifal l these recommendations are followed, Miller and Sanchez-Craig guarantee that 
success rates can double, triple or even quadruple, boosting them from a meagre 
20-30% to 80% and over. 
The issue of randomisation 
While Miller and Sanchez-Craig may be poking fun at the field, many of their 
'recommendations' - particularly the third ('avoid control or comparison groups') -
are widely followed. Although, in the short term, this may ease the pressure from 
funding organisations, in the long term, it is likely to have negative consequences for 
the validity of treatment evaluation and of treatments themselves. 
Problems related to lack of randomisation 
Because of practical and ethical constraints, clients have rarely been randomised 
into treatment and non-treatment samples, or even into groups under different treat-
ment conditions. The bulk of evaluation studies either examine only one form of 
treatment (without any control or comparison) or look at different programmes in 
which clients are self-selected. Typically, the effect of the treatment is then deter-
mined by comparing pre- with post-treatment behaviours. 
Obviously, applying non-controlled designs severely limits the reliability of the 
conclusions that can be drawn. Without randomisation, it is impossible to tell 
whether the observed change is truly an effect of treatment or of something else. In 
such situations, many confounding factors are free to exert their influence: 
• Although the moment of admission to treatment is by no means accidental (being 
related to an upsurge in an individual's severe problems), the moment of follow-
up is usually determined by the researcher. Purely on the basis of this difference, 
less problematic behaviour is likely at the time of follow-up. 
• Clients may over-exaggerate their problematic behaviour at intake, in order to 
convince the treatment staff of their need for help. 
• Conversely, clients may under-represent their problems at the time of follow-up, 
in order to reduce possible cognitive dissonance. In particular, this may be the 
case when the client has attended an intensive, long-term treatment programme 
with little or no success. 
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• In addition, under-reporting of problems at follow-up may be related to the client's 
wish to satisfy the therapist or treatment staff (the so-called 'hello-goodbye' effect). 
• Clients may assign different meanings to their problems during and after treatment 
(the 'response shift'). For example, they may view their problems as less severe 
because they have been confronted with other clients who have worse problems. 
As well as the lack of randomised control, the validity of outcome results may be 
threatened by a host of other factors, many of them already reflected in the 'advice' 
given by Miller and Sanchez-Craig. Two practical factors - which nearly every 
researcher in the addiction field has been faced with - deserve special mention: 
• High drop-out rates during treatment: typically the highest drop-out rates occur 
in the early weeks of treatment and then decline. 
• Low and selective response rates at follow-up: when using a longer follow-up 
period, non-response rates of over 50% are not uncommon. Non-respondents 
generally evidence more problems than respondents and are more likely to have 
unorthodox lifestyles. 
Problems related to randomisation 
Given the serious threats to the validity of outcome results caused by the lack of ran-
domisation, why is this method not applied more often in the addiction field? Three 
major problems affect the application of a randomised control design in 
naturalistic treatment research (De Leon et al., 1994a): 
• Ethical constraints: assignment to a 'no-treatment' condition, or to a 'more-
versus-less' treatment condition, actually means withholding services. 
• Practical constraints: clients in the 'no-treatment' group may seek treatment else-
where or may be referred to other programmes by family or courts, thereby causing 
research 'contamination' and 'within-group variance' in the 'no-treatment' control 
group. There are often high drop-out rates in the 'no-treatment' group prior to the start 
of the study (due to 'frustration bias'). This seriously breaches the requirement or 
assumption in randomised assignment that client-groups are comparable at baseline. 
• Logical flaws: in real life, clients often prefer a particular kind of treatment, which 
is reflected in the way they select one or another programme. The effect of treat-
ment at least partly depends on the client's readiness to engage in a specific form 
of it, and so - paradoxically - self-selection represents a prerequisite for treat-
ment effectiveness rather than a problem. 
Randomisation into different modalities or programmes may mitigate these differ-
ences in preference, but it also causes much 'within-group variance' as a result of 
client-treatment mismatches regarding motivation and readiness. 
Although mismatches may be randomly distributed between the two groups, the 
effect on the client may differ substantially (De Leon et al., 1994a). For example, the 
15 
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effect of a mismatch on a young client with a short addiction history and stable 
social environment who is randomised into a long-term therapeutic community is 
likely to be much greater than that on an older client with a long history of opiate 
use who is randomised into a methadone-maintenance programme. 
Hence, both randomisation and its lack may seriously threaten the validity of out-
come results in naturalistic studies. To find a solution to these problems, two alter-
native approaches have been suggested: 
• to apply non-randomised designs, providing an opportunity to compensate for the 
loss of 'power' of the randomised approach by incorporating into the evaluation 
information not only on the client, but also on the treatment and its process; or 
• to restrict randomisation to specific components within a treatment. 
The major problem encountered in both approaches, however, is that treatment is 
still very much a 'black box', and that neither treatment as a whole, nor the inter-
ventions within treatment, are well described or understood. 
How does treatment work? 
The questions of how treatment works, what are its active ingredients and what 
works for what kind of client can be approached from the following general regres-
sion model (Ball and Ross, 1991; De Leon era/., 1994b): 
Outcome = constant + client + treatment + process + error 
This model holds that treatment outcome is a function of a constant (people can 
change without treatment), a variety of client characteristics (demographic back-
ground, drug-use history, psychological status, etc.), treatment factors (type of treat-
ment, treatment goal, etc.), process variables (intensity and duration of the interven-
tion received by the client) and an error component (measurement error). With this 
general model as a background, the two approaches described above (non-
randomised and restricted randomisation) can be summarised as follows. 
Non-randomised approach 
This first approach aims to explore the relative contribution to treatment outcome of 
client characteristics and of those components related to the programme and process 
in a naturalistic design. 
Instead of controlling the influence of client differences through randomisation, this 
approach aims explicitly to trace those influences and to explore the interaction of 
client, treatment programme and process on outcome. Clients clearly vary in many 
respects and attend different treatments and follow divergent paths regarding the 
type of intervention received and its duration. Treatment outcome can therefore be 
measured by classifying these client-treatment trajectories, and by comparing the 
changes during and after treatment across the subgroups. 
16 
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Restricted randomisation 
The second approach can be applied to subsequent investigations of the effectiveness 
of specific treatment components (such as cue exposure) by means of randomised 
trials within the treatment under investigation. As mentioned above, the main problem 
with randomising clients into different treatments is that they nearly always have a 
preference for a certain type of programme (therapeutic community, detoxification, 
methadone maintenance, etc.). This preference does not exist to such an extent at the 
level of specific therapeutic components within a treatment, thus making controlled 
randomised trials feasible. Trials can be made using existing treatment components, 
but also by adding new components to 'treatment as usual'. 
To summarise, while the first approach aims to explore the contribution to treatment 
outcome of a full range of components on specific groups of clients, the second 
approach pinpoints the contribution to treatment outcome of a specific component 
on a full range of clients. 
While conceptually sensible, it is clear that the usefulness of the general model of the 
first approach ('exploration') depends on the ability to 'fill in' each of the boxes (client, 
treatment and process), and that - on the technical level - the practical application of 
this model depends on the use of quite complex multivariate regression techniques. 
Client, treatment, process 
Although a great deal of progress has been made in measuring client characteristics 
reliably, virtually no attempt has been made to study treatment or process variables, 
and no reliable and valid instruments exist to measure them. 
This bears directly on the so-called 'matching hypothesis', which states that some 
types of treatment or intervention are better suited to certain types of client than other 
treatments. According to McLellan and Alterman (1991 ), the lack of empirical support 
for the matching hypothesis may be mainly due to the lack of a reliable, valid, prac-
tical and generalisable instrument to measure treatment interventions. Clearly, in 
order to match clients to treatments and to investigate the effectiveness of this match-
ing, sufficient information is needed about both the client and the treatment. In terms 
of the general regression model, this means that the relevant variables in each of the 
model's boxes have to be identified and quantified using measurement instruments. 
The client 
Much progress has been made in measuring a wide range of client characteristics. Since 
the 1980s, there has been a shift towards a multidimensional assessment of functioning 
in various life areas (including health, substance use and psychology). This has been 
coupled with a move towards using standardised instruments, such as the Addiction 
Severity Index (ASI -McLellan et al., 1980) and the Opiate Treatment Index (Darke era/., 
1992), all of which can be used for both research and diagnostic or screening purposes. 
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Despite these developments, however, client factors have rarely been found to 
explain more than 15-20% of the variance in treatment outcome, thus leaving 
approximately 80% unexplained. This raises the question of whether the proportion 
of variance accounted for by client factors can be increased, for example by improv-
ing the quality, reliability and validity of measurement, or by widening the range of 
client variables collected. 
As for the reliability and validity of measuring client characteristics, a number of 
problems still remain. In particular, there are difficulties inherent in 'dual diagnosis', 
measuring co-existing psychopathology and its relationship to drug use. For example, 
in practice it is very difficult to distinguish between psychopathology and drug-
induced psychiatric symptoms, which may blur the prognostic significance of this 
factor in treatment. In addition, screening instruments in this area (such as the 
Symptom Check-List 90 (SCL-90), Personality Diagnostic Questionnaire (PDQ) and 
ASI) have generally shown high rates of false positives when compared to a 
categorical psychiatric diagnosis. 
Turning to the range of client variables collected, much can still be gained by focus-
ing on the so-called 'treatment-dependent' client variables (Kersten et al., 1995), as 
well as the 'treatment-independent' variables that are usually collected, such as 
demographic background, drug-use history and social functioning. 
Treatment-dependent client variables 
Treatment-dependent client variables only arise in the relationship between client and 
treatment, and refer to such factors as the type of help needed, the client's motivation 
for treatment and client expectations. These types of variables are rarely collected, and 
very few attempts have been made to develop standardised instruments in this area. 
According to the (mainly US) literature, three areas of treatment-dependent client 
variables may be important for prognosis and client-treatment matching. They 
should thus be considered when developing instruments (see Kersten et al., 1995): 
• the client's preference for a specific treatment; 
• the client's own 'addiction model'; and 
• the client's 'stage of change'. 
The client's preference for a specific treatment 
This goes back to the self-selecting process described earlier. According to Miller 
(1989) 'self-matching' is a prerequisite for successful treatment, and should be seen 
in terms of providing adequate information to the client about his or her treatment 
options, the content and purpose of the treatment and the likelihood of a positive 
outcome. Several researchers have found evidence to support the importance of self-
matching (Sanchez-Craig, 1980; Thornton et al., 1977). 
18 
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For the purposes of instrument development, self-selection issues should be explored 
and data collected on the role played by self-selection in the intake process. For 
example: 
• Does the client have a specific treatment preference? 
• Did this preference exist before information was given to the client, or did the 
preference result from the interaction between the client and intake staff? 
• Did the client actually undertake the treatment of choice? 
The client's own 'addiction model' 
This term refers to the client's general perspective on his or her addiction problems. 
There are two central questions here (Brickman ef al., 1982; Kersten er al., 1995): 
• Does the client feel responsible for the causes of his or her addiction? 
• Does the client feel responsible for changing his or her addiction? 
By similarly categorising treatments according to clients' views of their responsibility 
for addiction and change, clients may be matched to a treatment bearing the same 
philosophy. If, for example, the client does not feel responsible either for the causes 
of, or for changing, the addiction, then a medical treatment employing a disease 
model may be most appropriate. Several studies support this view (for example, 
Colon and Massey, 1988; Miller era/., 1993). 
The client's 'stage of change' 
In 1983, Prochaska and DiClemente postulated their now-familiar model of 'stages 
of change', which describes the process of achieving abstinence through the various 
stages of pre-contemplation, contemplation, preparation, action, maintenance and 
relapse or continued abstinence (Prochaska and DiClemente, 1983). 
According to these authors, many studies have demonstrated the significance of 
'stage-membership' for treatment prognosis (see Prochaska and Velicer, 1996), but 
others have challenged this conclusion and argue that strong empirical support for 
the model is lacking (Davidson, 1992; Farkas era/., 1996). Nevertheless, taken at 
face value the model has excellent validity and - as a model of change- has obvi-
ous applications. 
Regarding instrument development, several questionnaires have been developed to 
cover the 'stages-of-change' concept. Prochaska et al. (1988), for instance, produced 
the Processes of Change Questionnaire which measures ten such processes and 
which has been tested psychometrically in various studies (O'Connor ef al., 1996; 
Prochaska era/., 1988; Velicer era/., 1995). 
Several researchers have also developed instruments to measure client motivation for 
change or for treatment. For example, De Leon and JainchiII (1986) developed 
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Circumstance, Motivation, Readiness, Suitability (CMRS), and found empirical 
support for CMRS scores predicting treatment retention (De Leon ef al., 1994b). 
More recently, Miller andTonigan (1996) developed the States of Change Readiness 
and Treatment Eagerness Scale (SOCRATES) to measure the client's motivation for 
change. Given the importance of such motivation, each of these instruments should 
be examined for application and further development. 
Treatment 
Studies have rarely involved treatment or process variables in their evaluation 
model, other than using 'time in treatment' as an intermediate variable or simply 
describing the main type of treatment under investigation. The fact that 'time in treat-
ment' has consistently been found to be a strong predictor of outcome is an indica-
tion (but no more than that) that 'something' happens during treatment. An increase 
in the duration of treatment, however, should not be confused with having received 
more treatment, since clients may have received different amounts of treatment 
during a similar time period. Clients also differ in the amount of time they need to 
change. 
The reason why so many studies have disregarded this area is that it is very difficult 
to identify and quantify what happens during treatment - either from the client's or 
from the treatment's perspective. 
On a conceptual level, four basic sources of information about the treatment pro-
gramme and process can be distinguished. These information sources may serve as 
a starting point for future instrument development, data collection and evaluation 
research: 
Treafmenf: 
• general description of the type of treatment; 
• services offered to the client (type, intensity, duration). 
Process: 
• services received by the client (type, intensity, duration); 
• client change during treatment. 
General description of the type of treatment 
To isolate treatment variables effectively, it is necessary to understand what is 
actually meant by the term 'treatment'. This entails distinguishing between the main 
types and sub-types of treatment, and between its modality, goals, planned duration 
and accessibility. The following example (which has been adapted from the 
Pompidou Group's Drug Treatment Definitive Protocol) may serve as a framework for 
such a classification (Hartnoll, 1994): 
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Table 1 : Classification of types of treatment 
Types of treatment programme 
Specialised residential 
• hospital in-patient unit 
• therapeutic community 
• other (specify) 
Specialised outpatient/non-residential 
• hospital outpatient treatment centre 
• structured day-care centre/day hospital 
• local health/social-service centre 
• low threshold/drop-in/street agency 
• other (specify) 
General service-based 
• in-patient psychiatric hospital 
• outpatient mental-health-care centre 
• primary-health-care service 
• residential social-care facility 
• non-residential social-care facility 
• other non-specialised residential (specify) 
• other non-specialised non-residential (specify) 
Treatment unit in prison 
Type of treatment modality 
• detoxification/short-term reduction 
• longer-term drug substitution 
• medicament-free therapy/longer-term psychosocial treatment 
• advice/counselling/short intervention/support 
Goal of treatment 
• abstinence 
• stabilisation/harm-reduction/secondary prevention 
• behavioural change 
Planned duration of treatment 
• short (<1 month) 
• mid-term (1-6 months) 
• long (>6 months) 
Accessibility of treatment 
• waiting list (e.g., average duration previous year) 
• insurance coverage (yes/no) 
• 'motivation' required (e.g., threshold at intake: low/middle/high; 
abstinence required) 
• planned total duration of treatment (short, middle, long) 
• geographical location (urban/suburban/rural) 
21 
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Services offered to the client 
With respect to the second source of treatment information, it is preferable to collect 
data using the before ('intake') and after ('follow-up') format, as this provides an 
opportunity to link pre-, during- and post-treatment variables directly. 
One way to do so is to adopt a general instrument such as the Addiction Severity 
Index with its six problem areas, and collect information about the treatment pro-
gramme and process in each. For each area, the treatment's active ingredients should 
be described, as well as the extent to which they were offered to the clients. It should 
be noted, however, that much qualitative research is still needed to identify and 
quantify the relevant variables in each problem area. As an example, the domains of 
therapeutic ingredients and physical health are described in Table 2 below. 
Process 
There are two sources of process information: services received by the client; and 
client change during treatment. 
Services received by the client 
This area of information refers to the treatment elements that were actually received 
by the individual client during treatment or during a certain treatment period. 
Parallel to the factors discussed above, each component can be described in terms 
of the following: 
• services actually received by the client: type, frequency, duration 
• the result of these interventions: staff-rating 
• client satisfaction with these interventions: client-rating 
Information on the type, frequency and duration of services actually received by an 
individual client can be obtained through a treatment-registration system that should 
be carefully and regularly maintained. 
As for the second area of information, staff members who are actively involved with 
a particular client can be asked regularly to complete a questionnaire in which they 
rate the client's developments with respect to each of the areas described in the 
previous section (group therapy, individual therapy, family therapy, results of physical 
health interventions, etc.). The third area similarly informs the evaluator about the 
client's satisfaction with each of the interventions described in the previous section. 
C//enf change during treatment 
This final area of information is aimed at collecting data - as objectively as possible 
- about the ways in which the individual client changes during treatment with 
respect to each of the main areas described above (substance use, psychosocial 
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Table 2: Therapeutic ingredients and physical health 
Therapeutic ingredients: 
Substance use 
Psychosocial 
Therapeutic ingredients: 
Personal mentor available 
Group therapy: 
• no/passive/active/standard 
• supportive 
• confrontational 
• behavioural 
• cue exposure/relapse prevention 
• problem-solving/cognitive 
• bio-feedback 
• other (specify) 
Individual therapy: 
• no/passive/active/standard 
• psycho-analytical 
• supportive counselling 
• behavioural 
• cue exposure/relapse prevention 
• problem-solving/cognitive 
• other (specify) 
Family therapy 
• no/passive/active/standard 
Substance-use education 
• no/passive/active/standard 
Self-help (12 steps/NA/AA) 
• no/passive/active/standard 
Medication 
• no/passive/active/standard 
Additional ingredients: 
Physical health 
Employment/education/housing/financial 
Legal 
Social/family 
Psychiatric 
Physical health: 
Physician available 
Medical screening/check-up at intake 
• no/passive/active/standard 
Medical screening/check-up during treatment 
• no/passive/active/standard 
Health education: 
• no/passive/active/standard 
• general health/hygiene/sports/nutrition 
• drug-use risk behaviour 
Offered to clients: 
no/yes 
[type/frequency/duration] 
[type/frequency/duration] 
[type/frequency/duration] 
[type/frequency/duration] 
[type/frequency/duration] 
[type/dosage/frequency/duration] 
Offered to clients: 
no/yes 
[type/referral] 
[type/frequency/referral] 
[type/frequency] 
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functioning, physical health, employment, legal problems, social/family problems 
and psychiatric problems). At the same time as assessing the client's status at intake, 
an 'in-treatment' assessment can be conducted, using an instrument similar to that 
at intake and focusing on the client's situation during, for example, the previous 
month. 
The role of the EMCDDA 
When discussing the potential role of the European Monitoring Centre for Drugs and 
Drug Addiction in evaluating substance-use treatment in Europe, three aspects stand 
out: 
• the many difficulties involved in improving the general methodology of evalua-
tion studies; 
• the multitude of problems associated with identifying key variables and develop-
ing instruments, in particular in - but not limited to - the areas of treatment and 
process variables; and 
• the current low level of compatibility in data collection and evaluation methods 
within and between European Member states. 
It should be apparent from this chapter that there is an inherent friction between 
improvements in the first two areas and improvement in the third. Greater compati-
bility is often sacrificed to further refinements in data collection and methodology, 
and - conversely - studies that employ advanced instruments and methodology are 
often difficult to implement on a large scale. 
Given this tension and the current situation, the field of treatment evaluation at 
European level may best be served by a three-pronged approach: 
• In line with the Pompidou Group's effort to establish a definitive treatment-
demand protocol, modules may be developed to obtain core data not only on 
basic client characteristics, but also on basic programme, process and outcome 
characteristics. 
• A number of key projects should be initiated at European level, aimed at further 
developing advanced instruments that lend themselves to standardised data 
collection in the areas of client, programme, process and outcome variables (the 
COST-A6 development of the European Addiction Severity Index (EuropASI - see 
Chapter 10 below) is a good example). 
• Pilot studies should be conducted to test these advanced instruments in the con-
text of innovative evaluation strategies. Such studies should involve selected 
European treatment centres. 
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TREATMENT-EVALUATION LITERATURE 
Petra Paula Merino 
A literature review undertaken by the EMCDDA's Demand-Reduction Department to 
identify relevant treatment-evaluation literature revealed three major trends. One 
concerned scientific investigation, another managerial and economic interest, and 
the third clinical practice. 
Evidence of efficacy: scientific evaluation 
Treatment interventions in the drugs field vary widely across, and even within, coun-
tries. Often, these interventions are selected more for political or administrative rea-
sons than because of their actual effectiveness. In addition, concrete evidence of the 
benefits of targeting different approaches to different groups is lacking. In an attempt 
to redress this balance and to raise awareness of the effects of various treatment 
approaches, scientists have attempted to standardise the way information used in 
treatment-evaluation studies is collected and recorded. The two most commonly 
used techniques in evaluation research are retrospective, often naturalistic analyses, 
and prospective studies, either controlled clinical trials or randomised clinical trials. 
A third, less commonly used method is modelling. 
Health-care and treatment approaches based on concrete evidence are becoming 
more widespread. Such evidence is particularly important for guiding health-care 
policy-makers, and information can be derived from overviews, structured reviews or 
meta-analyses of clinical trials. The statistical data thus collected can be analysed to 
give an overall picture of a particular intervention, allowing conclusions to be drawn 
that would not be possible if data from a single trial were analysed. In the field of 
drug abuse, the Cochrane collaboration - involving participants from all over the 
world and from different drug-related disciplines - is establishing a group to review 
the existing literature on substance abuse. In doing so, it wil l amass evidence from 
all the relevant randomised-controlled and clinical-controlled trials in the field. 
From the scientific perspective, however, four major obstacles to treatment evalua-
tion remain: 
• the non-comparability of research findings; 
• disagreement about what constitutes successful treatment outcome; 
• the various measures used, specifically those related to drug use; and 
• the general absence of control groups. 
25 
THE THEORY OF DRUG-TREATMENT EVALUATION 
The non-comparability of research findings 
One of the major methodological problems facing drug-treatment-evaluation 
literature is that research findings are often not comparable. In an attempt to combat 
this difficulty, much effort is being made to collect information systematically on 
what works in drug-abuse treatment. 
The reasons for the non-comparability of research findings include: 
• a failure to compare like with like, and resistance to comparing competing 
approaches; 
• different client pools; 
• differences in timescales between programmes; 
• differing views of the goals of treatment; 
• the lack of a common language across disciplines to describe client populations, 
treatment progress and results; and 
• using research techniques of unknown validity and reliability which are often 
unique to the particular study. 
What constitutes a successful treatment outcome? 
Another major problem is reaching consensus on what constitutes a successful treat-
ment outcome. The majority of the literature views a successful outcome as the 
achievement of total abstinence from drug use. As such, many studies use the rate of 
total abstinence as the primary - and sometimes sole - criterion for evaluating a 
treatment as 'successful'. Some other studies similarly report the frequency of sub-
stance use, while still others record the time span involved and rates of relapse. In 
addition to abstinence and substance use, the employment and socio-psychological 
condition of clients may also be explored. 
Research into the effectiveness of different treatment approaches tends to point to the 
need for better patient-treatment matching and care systems. If the chosen indicators 
of effectiveness do not match the patients' own criteria, these patients may leave the 
care institutions prematurely (Arino et al., 1988). In much of the treatment-evaluation 
literature, there is a clear awareness of the need to modify the criteria currently used 
to match clients to appropriate treatment and to take the individual patient's needs 
into greater consideration. 
Measures of drug use 
The existence of various methods of measuring drug use is another feature of the 
evaluation of treatment. All these methods have their limitations, and little is 
currently known about their impact on the interpretation of treatment outcome 
(Martin ef al., 1989). In addition, different measures of drug use may produce dif-
ferent results, making cross-study comparisons difficult (Wells ef al., 1988). Since 
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those who abuse psychoactive drugs tend not to confine their use to one single drug, 
the resultant drug-dependent behaviour exhibited can be very complex. 
The general absence of control groups 
The tendency in the studies identified by the EMCDDA's literature review is to assert 
that the change measured is due solely to the treatment intervention itself. Factors 
identified include the inclination to apply outcome measures only to those 
individuals remaining in treatment while ignoring drop-outs, and the general 
absence of control groups for ethical reasons. The ethics of using control groups 
made up of those with severe drug problems to whom no assistance is given is 
highly problematic. The study of drug-abuse treatment has frequently been divorced 
from the study of the drug user, who is generally viewed first and foremost as a treat-
ment client rather than as a drug user. Nevertheless, the user in treatment is, in cer-
tain respects, atypical. As a result, looking at drug users' needs solely from the point 
of view of treatment services and the approaches they provide means that a signifi-
cant amount of information about the users themselves that could be of great value 
in improving drug-treatment interventions is not taken into account. To identify the 
users' real needs requires going beyond the service that is already being provided. 
Programme management: cost-effectiveness and economic evaluation 
In the past decade, major improvements have been made to the quality of pro-
gramme planning and management in health-care services. These include assessing 
users' needs and evaluating costs and effectiveness in a systematic way to create 
clear policies on allocating the resources available. Evaluating treatment approaches 
is now seen as an integral part of programme management rather than as a purely 
scientific function, as was the tendency previously. Cost-effectiveness evaluations 
may be undertaken for one of two reasons - accountability or 'improving quality'. 
Substance-use services can be evaluated on many levels, including treatment activ-
ities and components, treatment services, treatment programmes and agencies, and 
treatment systems (WHO, 1997). 
In terms of accountability, treatment programmes are evaluated to demonstrate their 
effectiveness to the funding sources. Accurate evaluations are required to allow pro-
grammes to be differentiated and to advise policy-makers on the quality of the 
different interventions. Programme-designers and managers face growing pressure to 
balance the costs of delivering a service with its results. Cost-effectiveness is thus 
often viewed as auditing, and not as process evaluation. In most countries, 
economic evaluation is intended to maximise health care using available, and often 
limited, resources. A genuine economic evaluation requires two key elements: 
• it must compare inputs or cost and outputs or effects; and 
• it must compare alternative treatments. 
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Clinical practice: treatment-progress evaluation 
There is a clear division between actual clinical methods and experimental investigations 
(Miller ef al., 1995). The former has determined the standards for clinical practice, while 
the latter has generated the majority of the controlled studies found in the literature. 
With growing pressure to remain within ever-tightening budgets and to justify their 
actions to funders and other external bodies, clinicians may be unable to provide the 
necessary data about their particular service, especially if they are not involved in 
the process of evaluation. Furthermore, these practitioners are unlikely to create 
their own evaluation programmes because they do not wish to see external control 
imposed on their decision-making and because many current evaluations lack real 
clinical value. 
In Europe, valid and reliable instruments are being sought to assess treatment out-
come across a broad range of drug-related problems and so enhance cross-study 
comparability. There are, however, different views of which instruments can serve 
clinical purposes or objective research purposes (Darke ef a/., 1992). Instruments are 
also used for specific objectives in service delivery, including its economic and man-
agerial aspects. 
From the clinicians' point of view, the ideal evaluation instrument should: 
• have clinical and research applications; 
• be brief and easy to administer; 
• be usable by both medical and non-medical staff; 
• be understandable to clients; 
• define admission; 
• match clients to the appropriate level of care; and 
• measure treatment progress. 
Conclusions 
The literature available on the evaluation of drug-abuse treatment derives mostly 
from scientific research. Yet it is still rare for this knowledge to be transferred 
adequately from the scientific level to that of current European practice. As a result, 
treatment strategies based on little scientific evidence are still often used. 
A considerable amount of the information likely to be gathered in the course of 
clinical practice is lost because of the difficulties encountered by professionals in 
registering data systematically. 
Treatment evaluation can also help to improve the delivery of treatment services, 
including their managerial and economic aspects, but these types of evaluations 
appear less frequently in the literature. The development of innovative reporting 
mechanisms on the Internet, based on current evaluation practices to improve ser-
vice delivery, should increase the culture of evaluating the treatment of drug abuse. 
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EVALUATING RESIDENTIAL 
AND INSTITUTIONAL TREATMENT 
Mats Fridell 
Three basic concepts in evaluation research are often treated as if they were 
synonymous, despite the fact that they represent very different aspects of the process. 
These concepts are productivity, effectiveness and quality. The first two are fairly 
similar and can be assessed in economical and other objective terms. The concept 
of 'quality', on the other hand, involves a number of subjective and attitudinal fac-
tors, such as the needs and expectations of both the providers and 'consumers' of 
drug services. These concepts need to be defined if what it is that is being evaluated 
is to be understood. 
Productivity describes the relationship between achievements and resources, while 
effectiveness is the relationship between effects and resources. The 'effectiveness' of 
a production unit can thus increase even if there is an overall decrease in existing 
resources ('rationalisation'). Cost-effectiveness can also increase when extra 
resources are made available, but only when the increase in effect is proportionally 
larger than the quantity of resources added. Finally, quality is the relationship 
between the actual level of service as experienced by its users and providers, and 
the expected level of quality (Dertell, 1989). In assessing quality, not only should the 
perspective of the treatment provider be taken into account, but also the subjective 
experiences of the treatment users - which are perhaps even more relevant. 
Scientific and pragmatic perspectives of 'quality' of service may well diverge 
markedly in such a situation. 
To confuse the issue further, 'quality assurance' is another recent popular concept 
(Hansson ef al., 1993; Kelstrup ef al., 1993). Even if the concept itself lacks precision, 
it nevertheless indicates a need to consider objective issues alongside the assessment 
of clients' subjective experiences (Vuori, 1991). After assessing the quality of the 
ongoing treatment or its setting, the final stage is 'quality management'. This refers 
to the strategies used to implement and optimise quality goals (Fountain, 1992; 
Fridell, 1990). Systematic approaches, such as the 'client-treatment matching' 
described earlier, are promising - if not exhaustive - applications of quality man-
agement (McLellan et al., 1983; MATCH Research Group, 1997). 
Most evaluation studies focus on the effects of a defined intervention. 'Effect' and 
'effectiveness' do not, however, refer to exactly the same domains. The latter con-
cept might be used to indicate an increase in effect within the same treatment 
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modality at a given point in time. In contrast, the former concept refers to the rela-
tive difference between two treatment methods or between a specific method and 
control groups which receive an alternative treatment or placebo. One of the main 
differences between the two concepts is that while methods to enhance effectiveness 
in one treatment setting may not easily be transposed to other settings, a randomised 
study of treatment effect can usually be compared to other treatment settings and 
groups. Such meta-analyses are measured in terms of 'efficacy' (Smith et al., 1980; 
Crits-Christoph, 1992; Crits-Christoph and Siqueland, 1996). 
However, in evaluating residential treatment, concepts such as 'effect' and 'efficacy' 
lose their precision, and it may be simpler to use the more modest term 'treatment 
outcome'. 
Within an institution, such outcomes may be related to variations in the effectiveness 
of the intervention's implementation as well as to variations in client selection. Such 
a definition of 'outcome' may make it less easy to compare different treatment 
settings or modalities, but it remains a necessary ingredient for 'productivity control' 
and 'quality assurance' within the institution. 
The problem of representativeness 
In order to generalise research findings so that they can inform the whole treatment 
sector, patient-selection mechanisms need to be controlled. Samples entering different 
treatment modalities may differ substantially in outcome-dependent variables, such 
as psychopathology, gender or motivation. 
Another problem facing evaluation studies is that many research concepts and tech-
niques will be very imprecisely applied in the 'real world'. A specific therapeutic or 
pharmacological treatment may be applied very differently in the actual treatment 
setting than in a randomised control field trial, while issues familiar to researchers, 
such as 'consecutive samples', for example, are of little value if comparisons 
between experimental and control groups are lacking. Perhaps the only way around 
these difficulties is to regard the treatment modality itself as an intermediate rather 
than as an independent variable. 
Randomised control design 
As already outlined in Chapter 1, the method of choice in evaluating medical inter-
ventions is the so-called 'randomised control design'. This is easy to use in experi-
mental animal research, because the 'learning curve' of the animals can be cut short 
by killing them so that skills learnt in one setting cannot be exported to another. 
Clearly, there could be problems if the same techniques were used in field settings 
on humans. 
Alongside the ethical considerations touched on elsewhere in this monograph, 
another major methodological problem is that of internal consistency in data 
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collection. The risk is that only some clients wil l be assessed on all the variables and 
across all the conditions, a situation that threatens the study's validity. 
Furthermore, organisational variables must be included in controlled studies if any 
scientific explanation and interpretation of treatment outcome is to be made. A sys-
tematic application of this hypothesis on existing empirical research in residential 
settings was recently published by the author (Fridell, 1996a). 
Finally, long-term follow-up is another dubious area when focusing on treatment 
effects, as changes over time in lifestyle and general socio-economic conditions 
must be expected to influence the individual's behaviour more than the specific 
treatment intervention made several years earlier. 
These obvious problems, however, have done little to discourage randomised con-
trol trials (RCT). A recent Medline search from January 1998 included 647 studies 
defined as RCT on drug addiction only. Treatment studies on alcohol were not 
included. There were 90 studies of psychosocial treatment methods and ten RCT 
studies on institutional treatment as well as a large number of high-quality cohort 
studies (see, for example, Ravndal and Vaglum, 1992; Bale et al., 1980; Bell, 1985; 
McLellan et al., 1993; Woody et al., 1987). In addition to pharmacological studies 
on drug addiction, 247 RCTs were registered in Medline by January 1998. Reviews 
and meta-analyses of these psychosocial and pharmacological trials wil l be pub-
lished by the Swedish Council on Technology Assessment in Health Care (SBU) in 
spring 1999. 
The use of standardised instruments 
The quality of any evaluation study - whether random controlled or otherwise - can 
be increased by consistently using a thorough common screen on all the clients, 
coupled with other standardised instruments that allow comparisons to be made 
between relevant client groups. This should also make it easier to compare the group 
against itself on a number of vital variables at follow-up. 
It is important to pre-determine the validity and reliability of any assessment mech-
anism that was used in previous outcome studies. Anglo-American assessment 
instruments are most easily obtained at present, but any use of internationally 
accepted methods without good psychometric properties can only give a false basis 
for precision. 
Although such instruments are plentiful in the alcohol field, they are not quite as 
common when it comes to drug use. Perhaps the most prevalent (and most regularly 
tested for validity and reliability) today is the Addiction Severity Index (ASI), which 
has been translated into a number of European languages. As Chapter 10 shows, a 
European version, EuropASI, has also been developed. 
The ASI is used for individual assessment as well as group description, screening and 
follow-up (McLellan et al., 1980, 1985, 1992; Kosten et al., 1992). Long as well as 
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short versions are available, and it has been adapted for various abusing groups, such 
as the homeless or young people (Friedman and Utada, 1989). ASI can be 
easily combined with other measures like the Symptom Check-List 90 (SCL-90 -
Derogatis and Lipman, 1973; Derogatis, 1994) and the American Psychiatric 
Association's Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnoses. 
As personality disorders are diagnosed for 65-85% of clinical groups, and 30-60% 
have been found to have moderate-to-severe depressive and anxiety disorders, 
personality-assessment instruments must be included (Fridell, 1990, 1991, 1996b). 
The most frequently used diagnostic systems for personality disorders are the third 
edition, revised, and the fourth edition of the DSM (DSM-III-R and DSM-IV), facili-
tating international and national comparisons of patient groups. The diagnoses can 
be assessed either by clinical or by standardised interviews (Skodol ef al., 1988; Skre 
et ah, 1991). 
As the DSM system is based entirely on a description of an individual's behaviour, 
clustered into sub-categories, it does not measure personality traits. A number of 
theory-based personality inventories and tests have therefore been developed to 
complement the formal DSM diagnoses. These inventories vary, however, as to their 
sensitivity in measuring change, their theoretical perspectives and their construct valid-
ity. Some are very stable over long periods of time, while others are more sensitive to 
change. Scales and tests should thus be selected on the basis of the primary research 
issue. 
The most frequently used scale today is the Minnesota Multiphasic Personality 
Inventory (MMPI - Craig, 1979, 1980). Several hundred studies have employed 
MMPI data and a number of abbreviated scales exist, as well as some that have been 
specifically tailored to drug-related personality problems (Fridell, 1991). 
Other scales that reflect severe personality disorders include Gunderson's Differential 
Diagnosis for Borderline and a Swedish implementation of Kernberg's tripartite model 
of psychological organisation, the Rating Ego Balance (Sandell, 1994). The latter 
has been used for epidemiological diagnostic purposes on large numbers of social-
welfare clients with substance disorders in Stockholm (Bertling et al., 1993; Sandell 
and Bertling, 1996). Still in Sweden, the Cesaree Marke Personality Scheme measures 
psychogenic need (Cesaree and Marke, 1968; Bech ef al., 1986; Hallstrom et al., 
1986; Holmlund, 1990). A short inventory measuring Basic Character Traits has also 
been developed over the last 15 years and is presently being standardised for large-
scale use (Kline and Storey, 1977; Sandler and Hazari, 1960; Cesaree, 1980; Cesaree 
and Fridell, 1997). Another frequently used instrument is the Eysenck Personality 
Inventory (Eysenck, 1959; Eysenck and Eysenck, 1964), while the Karolinska Scale of 
Personality is also used, largely on alcoholic groups (Klinteberg et al., 1986). Finally, 
the Psychopathy Checklist- Revised is, in this author's view, an underrated although 
internationally acclaimed psychiatric scale. It is of great value for studying drug 
dependence where anti-social behaviour can be easily confused with stable psycho-
pathic traits, a factor which complicates the interpretation of test results and their 
application (Hare ef al., 1991; Klinteberg étal., 1992). 
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Various promising scales also deal with the social network of drug misusers. In 
Sweden, the Australian-developed Individual Schedule for Social Integration has 
been widely applied (Henderson et al., 1980; Undén and Orth-Gomér, 1989; Orth-
Gomér and Johnson, 1987). 
Finally, returning to evaluating organisations and residential treatment, measuring 
the 'therapeutic climate in an organisation' has proved to be a meaningful and 
scientifically valid approach. The kind of measurements obtained involve staff as 
well as clients. The rationale is that organisational factors such as 'climate' and 'cul-
ture' reflect the selection of patients, staff competence, working relations and 
conflict levels. The most common instrument is the Ward Atmosphere Scale (Moos 
and Houts, 1968; Friis, 1986; Collins et al., 1985), which has been widely used in 
Scandinavian residential treatment studies. 
In summary, for any form of evaluation, a number of different measurement instru-
ments should be applied, for instance, self-assessment questionnaires, interview data 
and register data which should be used simultaneously. A research design of this 
kind is usually known as 'method triangulation' (Cook and Cambell, 1986). 
Influencing outcome 
Just as it involves a wide array of instruments and theories, evaluating drug treatment 
includes many design problems, complicating the comparability of treatments. 
Spontaneous remission 
One of the most influential myths that still survives today was launched by Charles 
Winnick in the early 1960s. He tracked substance misusers on New York State's 
narcotic registers, and those that were listed in the mid-1950s, but did not appear 
five years later, were classified as cases of 'spontaneous remission' (Winnick, 1962, 
1964). Interestingly, an early repeat of this study could not support his very opti-
mistic figures (Snow, 1973). 
A number of prognostic studies on drug abuse exist, but one of the more qualified 
reviews reached very different conclusions from those of Winnick (Maddux and 
Desmond, 1980). This study found that the levels of possible spontaneous remission 
were very seldom greater than 20%. This author's own overview of existing data 
concludes that spontaneous remission is in the range of 10-15% (Fridell, 1991). 
When evaluating the impact of 'spontaneous remission' on any treatment, the client 
base must be taken into account, as must the quality and quantity of an individual's 
social network. Schizophrenic drug misusers may have spontaneous remission rates 
of 0%, while maybe 95% of adolescents experimenting with drugs wil l sponta-
neously remit (Fridell, 1996b). 
The drug that is being misused is another factor in evaluating 'spontaneous remis-
sion'. Prognostic studies of opiate users indicate a much lower level of abstinence at 
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follow-up than is the case with other drugs. According to Haastrup and his 
colleagues, in the 1970s and 1980s early death was in fact the main factor con-
tributing to the 'decrease' in opiate misuse at cohort follow-up (Haastrup and Jensen, 
1988). 
Attrition 
Twenty years ago, the drop-out rate from treatment was extraordinarily high and out-
come was often calculated for a mere 10-15% of the original patient cohort. 
However, it was also found that well-functioning institutions had lower drop-out 
rates than poorly functioning ones. Thus, by the, 1980s, some therapeutic commu-
nities were beginning to succeed in lowering drop-out considerably (Vaglum, 1979; 
Berglund ef al., 1991). Today, it seems that some 30-40% of clients graduate from 
treatment, while studies also indicate a minimum length of treatment of 3-6 months 
before any substantial change takes place (DeLeon, 1991). The 'best' drop-out rates 
this author has come across are from a therapeutic community in New York, organ-
ised around the ideas of Daniel Casriel, with an annual drop-out rate of just 20% 
(Winnick, 1962). 
One of the more substantial conclusions drawn from 30 years of research is that drug 
abusers recover as a function of time in treatment. This also seems to be the case for 
those dropping out of treatment (DeLeon, 1984; Condelli and Hubbard, 1994). To 
keep the individual in the treatment system, therefore, seems to be vital to the out-
come. Of about 50 empirical studies supporting this conclusion, only one to date 
has presented an opposing view (McCusker et al., 1995). However, which variables 
predict drop-out is still unclear (Fridell, 1991). A recent multi-centre study compar-
ing 'static' factors (such as gender, age and drug of misuse) with 'dynamic' factors 
(contact at admission interview, etc.) found that the best predictor of retention was 
the interviewer's rating of client motivation (Condelli and Hubbard, 1994). This was 
followed by whether the client spent most of the time with groups of people or pre-
ferred being alone. The third most important variable was external pressure to seek 
treatment. 
So far, few studies have accounted for the influence of organisational variables on 
treatment outcome. But, as personality disorders are the dominant problem among 
drug-dependent patients, treatment structure and programme clarity remain factors 
of major importance (Fridell, 1990, 1996b; Ravndal, 1995). 
Single or multiple criteria 
The classic drug-treatment perspective is that the client must improve in more 
respects than just their use of drugs. There is considerable empirical support for such 
a position today. The most relevant - and pessimistic - application of multiple 
criteria is a model presented by the SWEDATE project, using cumulative criteria 
(Berglund ef al., 1991). This found that a follow-up which only took into account 
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abstinence from drugs had a general success rate of 50%. When alcohol use is 
added, this level decreases to 40%. If successively more and more criteria are 
included, the rehabilitation figures plummet and, finally, only some 10-14% wil l be 
completely rehabilitated and free from psychological suffering. 
It is important to note, however, that several misconceptions are built into such a 
critical appraisal. The first is that medical and psychological treatment never expect 
a person to be completely cured. The second, and perhaps more important, issue is 
that such a criterion as psychological well-being is inappropriate, as only 40% of 
heavy drug misusers at a recent five-year follow-up fulfilled this criterion, regardless 
of whether they were abstinent at this point or not (Fridell ef al., 1996). On the 
positive side, several recent reviews of the treatment of heavy drug use have con-
cluded that success rates in treating substance disorders are as high or higher than 
in many other chronic ailments (O'Brien and McLellan, 1996; O'Brien, 1996; Crits-
Cristoph and Siqueland, 1996). 
Short- or long-term follow-up 
A common ¡deal is to discuss outcome in terms of one- or two-year follow-ups. Very 
often shorter-term perspectives, such as goal attainment at discharge from acute or 
short-term rehabilitating services, are overlooked. This creates problems when 
trying to compare levels of goal attainment in, for example, psychiatric departments 
and therapeutic communities. Differences in goals and focus must therefore be taken 
into consideration. 
On the other hand, patients admitted to a psychiatric ward can be expected to have 
more severe as well as longer-term problems. The need to train staff to maintain 
good-quality care for these patients is clearly vital if future and long-term treatment 
efforts are to be motivated. Quality of treatment (and sometimes its lack) is probably 
as important in the short term as it is in the long term, even though the foci of treat-
ment vary. 
Simple goal-attainment procedures can therefore be highly relevant when measur-
ing short-term interventions (Kiresuk and Sherman, 1968; Kiresuk, 1973). Goal 
attainment is, in its own right, a rather sensitive measure of organisational stability, 
and it has been successfully used to increase staff participation in the treatment 
setting (Fridell, 1990). It is important to note that an unmotivated patient can be 
positively motivated by an empathetic staff member and, likewise, that a motivated 
patient can lose motivation because of indifferent 'care'. 
The quality of daily care thus needs to be high, regardless of the fact that it might not 
increase long-term outcome as far as is known today. An illustration of this is a 
randomised control study from Finland which compared treatment in a therapeutic 
community with the ambulatory treatment of heavy problem drinkers (Keso and 
Salaspuro, 1990). All the patients were included in the study, and one-year follow-
up found a somewhat larger improvement for those in residential treatment. These 
patients generally reported a higher level of satisfaction with treatment, which was 
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also reflected in a more positive evaluation of institutional climate as measured by 
the Ward Atmosphere Scale. The differences in complete abstinence and controlled 
drinking between the two groups, however, were not significant. 
This illustrates the difference between the satisfaction of quality experienced in a 
defined setting and the issue of treatment outcome. The study does not, however, 
answer the question of which treatment is best. To do so, a representative sample of 
therapeutic communities must be compared to a representative sample of ambula-
tory care facilities. 
Conclusions 
Despite the vast amount of treatment-evaluation literature, a number of misconcep-
tions still exist. The first is that treatment strategies in general are ineffective and that 
treatment yields only modest levels of success. However, empirical research 
demonstrates that treatment can be very effective, and several recent reviews show 
a considerable success rate using psychosocial and therapeutic modalities 
(Crits-Christoph and Siqueland, 1996). The problem is more one of /'nfra-modality 
variation (between, for example, US and UK therapeutic-community models) rather 
than one of /nfer-modality variation (for example, between therapeutic communities 
and psychiatric in-patient units). 
Despite this evidence, the problems of evaluation still cause heated debate and 
engender a number of conflicting views. One of these is the reference to what 
should be regarded as a basic 'non-treatment level', such as the issue of high spon-
taneous remission. Another is that evaluation itself has demonstrated that drug mis-
users are a more heterogeneous group than was previously believed. Questions 
about proper comparison groups, self-selection, spontaneous remission and the type 
and degree of psychiatric disorder have consequently become more and more per-
tinent, and more vital to interpreting outcome. 
Over the last decade, much attention has been paid to client-treatment matching 
factors, such as psychiatric disorders, gender or other specific subgroup issues, since 
these areas might indicate the need for a specific intervention, increasing the prob-
ability of a successful outcome. The need fora diverse continuum of criteria for treat-
ment evaluation is therefore necessary, especially where the otherwise obvious goal 
of abstinence might be secondary to reducing risky behaviour or stabilising 
psychiatric symptoms. 
This chapter has examined some of the most central issues in evaluating residential 
treatment. Different and complementary research approaches must also be consid-
ered, whether the basic aim is to study effects, outcome or quality assurance. No 
single research design provides answers to all these diverse fields, and many - if not 
most - of the problems related to institutional treatment might be better approached 
by models other than the standard procedures of randomised control studies. 
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METHODOLOGICAL ASPECTS 
OF TREATMENT EVALUATION 
Fabio Mariani 
In any thorough evaluation of drug treatment, it is crucial to define the 
characteristics of those people undergoing the treatment. It is commonly assumed, 
however, that 'abuse' and 'dependence' - perhaps the most fundamental 
characteristics of anyone being treated for drug problems - are almost impossible 
to define, observe, measure or differentiate. This assumption is erroneous, as much 
of the research over the last 40 years has demonstrated. 
That said, it can be difficult to distinguish between 'abuse' and 'dependence' in an 
individual, as so much hinges on the personality of the user and the relationship 
between drug use, dependence and socio-cultural aspects. Physiological and 
environmental factors, together with drug careers ('drug, set, setting'), are the most 
familiar of the many confounding factors that can influence the evaluation of 
treatment effects. 
In the American Psychiatric Association's Diagnostic and Statistical Manual of 
Mental Disorders (DSM), the concept of a 'psychoactive substance dependence 
disorder' is defined as undesirable behaviour associated with regular drug use, 
rather than as an acute or chronic drug reaction. The Manual's account of 
substance dependence is simply a codification of common sense. People who 
display a number of the following symptoms are said to be 'dependent' on a drug: 
• repeatedly taking more than intended or for longer than intended; 
• knowing they are using too much, but being unable to stop; 
• spending much of their time either obtaining the drug, intoxicated or recovering 
from the drug's effects; 
• being unable to fulfil social, familial and work obligations because of 
intoxication; 
• giving up most other activities in order to use drugs; 
• continuing to take the drug although they know it is damaging their health, work-
ing capacity or family life; 
• developing tolerance, making it necessary to raise the dose to preserve the orig-
inal effect; 
• withdrawal symptoms; and 
• constant use of the drug to relieve or avoid withdrawal symptoms. 
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Comparative evaluation and confounding factors 
The 'perfect treatment' is an unattainable holy grail. Undesired and unplanned short-
and long-term collateral effects will always affect a treatment for some people in 
some particular application or circumstance. In such cases, it is vital to evaluate all 
possible outcomes, whether positive or negative, and not just those that are the 
object of study. Generally speaking, it is also inadvisable to examine the efficacy of 
one treatment to the exclusion of all others as there are many treatment modalities, 
each with their own measures of effectiveness and efficiency. 
Effectiveness evaluation must therefore be comparative, as it is necessary to demon-
strate how - and to what extent - one particular treatment is 'better' than another. If 
no other treatments are available, the treatment being evaluated should be com-
pared with the natural evolution of the situation, either in the absence of therapy or 
in the presence of a placebo. 
The advantage of a comparison with a placebo 'treatment' rather than with natural 
evolution is that it aims to counter the psychological effect of treatment. The main 
hurdle to this type of comparative study is the problem of implementing the study 
protocol effectively in a 'double-blind' procedure in which neither those submitted 
to the placebo nor those 'treating' them know that they are in this situation. 
A further important point is the near impossibility of finding treatments or placebos 
that can be adequately compared. Consequently, the judgement of effectiveness will 
tend to be established as a probability of success, estimated by the ratio between the 
number of cases with favourable outcomes and the total number admitted to treat-
ment. For this reason, it is important to know if the distribution of positive outcomes 
in the treated group is related solely to the treatment modality or whether it is related 
to other factors or causal effects. 
Finally, two other aspects which could influence the choice of treatment need to be 
considered. The first factor is whether a particular treatment is the 'best fit' for the 
client group. If so, proof of its efficacy should be available for subjects with similar 
characteristics. The second factor - and one without which no treatment evaluation 
can be effectively performed - is the acceptability of the treatment to the client. 
Randomised control trials 
As already stated, the best way to evaluate an untried treatment is to organise the 
study with two experimental subject groups, the first being submitted to the treat-
ment, and the second ('the control group') to a placebo or already-evaluated 
treatment. This could include prevention programmes, rehabilitation, in-patient and 
outpatient interventions, and true placebos. 
For the evaluation to have any scientific validity, subjects must be assigned randomly 
to the two experimental groups, although the full 'pool' of subjects should be as sim-
ilar as possible and certain factors should be identified as 'matching' variables to avoid 
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any confounding factors or an uneven weighting between the two groups. The best 
way to do this is to work with the most specific group of subjects as is practicable. 
Similar age ranges, gender distribution, substance-use history, family situation, socio­
economic and psychological characteristics should all be considered, so that the final 
assignment to either group can be a true picture of the target client population. 
The more time and effort that is spent characterising, defining and limiting the target 
population the more specific that population becomes and the easier it is to limit the 
number of variables under consideration. On the other hand, the wider the group, 
the more difficult it is to define objective criteria to describe their characteristics and 
measure treatment outcomes. One method that is frequently employed to define the 
groups is to stratify the sample in terms of prognostic factors, during both enrolment 
and data analysis. 
Stratification during enrolment allows for an increase in statistical accuracy as the 
main exclusion of confounding factors takes place at the outset, allowing clinical out­
come to be closely related to the prognostic factor. Stratification during data analysis, 
however, risks limiting the evaluation to extremely small numbers of subjects. For 
example, if at this stage three main strata were defined (gender, age and clinical fac­
tors) which all had a number of internal strata (male/female; <18 years, 18-24, >25 
years; opiate use, polydrug use) then by the end of the process there would be 3 χ 2 χ 
2 strata for each experimental group, in other words, 24 strata in total. The likelihood 
of finding many subjects in the same strata would therefore be extremely low. 
Defining the inclusion criteria 
Clearly, any evaluation must begin by defining precise criteria for including its sub­
jects in the study. Client characteristics and methodologies for data collection should 
also be defined at this stage. Moreover, all subjects presenting specific contra­
indications for any of the treatments under examination should be excluded. For 
example, seropositivity and the possible development of AIDS cannot be ignored 
when providing certain treatments, especially placebo 'treatment'. 
If the aim of the study is simply to select a treatment that is more effective than 
another, inclusion criteria can be less strict than when the aim is to compare and 
elucidate different modalities of action within different treatments. In any case, both 
the diagnosis and the severity of the pathology should be defined for each subject to 
allow for analysis according to accuracy and repeatability. 
Defining the therapeutic protocol 
One of the most important aspects of research is the possibility of repeating a study 
in various contexts. In the context of treatment evaluation, this requires a detailed 
definition of therapeutic protocols for different treatments. In the case of drug depen­
dence, the physiological and social aspects of clinical, biological, pharmacological 
and compliance issues also need to be considered. 
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Defining the major outcomes 
Drug-free behaviour is clearly the ultimate desirable outcome when considering any 
treatment evaluation. But to characterise such behaviour better, a number of sec-
ondary outcomes on the road to abstinence must be defined. 
In general, a certain variability exists between professions when formulating any diag-
nosis, defining prognostic factors or describing outcomes. For an effective evaluation, 
all these possible criteria must not only be clearly defined, but also capable of objec-
tive measurement. Observations made by professionals should therefore be accurate 
(in other words, close to the phenomenon being observed) and easy to repeat 
(observations of different professionals concerning the same issue and of the same 
professional at different times should elicit the same results). All the variables under 
consideration should be examined using standard criteria and modalities, and any new 
criterion should also take account of accuracy and repeatability. 
In any multi-site study, and often in longitudinal studies too, quality control is vital. If 
the outcomes under evaluation can be subject to differing professional theoretical con-
ceptions, it is important to guarantee that data collection is performed by researchers 
with no stake in the outcome. In other words, they have to be part of the 'double-blind' 
aspect of the study, having no past knowledge of the treatment under evaluation. 
Confounding factors 
One of the major sources of distortion during any evaluation study is the unforeseen 
impact of additional diagnostic and therapeutic factors not considered by the original 
protocol. This kind of distortion is of particular concern in the drug field, as even 
small, apparently unrelated variations in a subject's micro or macro environment 
(such as family tension) can have far-reaching effects. 
Effect of drop-out on data analysis 
Knowing what has happened to those who have dropped out of treatment is just as 
important as knowing about those who have remained in the study. Clearly, if they 
have left it may be impossible to follow them up, but it is usual to 'cancel them out' 
against individuals who complete treatment. For example, a positive outcome 
should be applied if the drop-outs belonged to the group showing overall negative 
reactions, and a negative outcome should be applied if they belonged to the group 
with more positive reactions. 
Clinical and statistical significance 
Clinical significance refers to the importance placed by researchers on the differ-
ences in clinical developments between the two groups under comparison - for 
instance, in relation to the incidence of relapse, mortality or seroconversion. 
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Statistical significance, on the other hand, only indicates that the observed difference 
is probably related to the treatment, without implying any judgement as to the 
clinical value of the variation. 
Other forms of evaluation study 
A number of other experimental, as well as observational, studies can be used in 
treatment evaluation when randomised control trials are seen to be impossible or 
inappropriate. 
As already stated, in experimental studies the researcher defines the inclusion crite-
ria for making up groups, as well as criteria for selecting treatment. In observational 
studies, on the other hand, the effects of treatment are simply analysed without any 
specific research design. 
Observational studies can be useful when a body of experimental evidence already 
exists and the effectiveness of the routine application of a treatment needs to be 
assessed. But, whatever the case, when choosing a particular study design it should 
always be remembered that whenever the scientific basis for a treatment being 
better than another is low, greater methodological accuracy is needed. 
Non-randomised control studies 
This form of experimental design is similar to that already described, the only differ-
ence being that inclusion in a particular group and enrolment in treatment are not 
random. 
In this case, researchers explicitly assign subjects to the different treatments. It is 
therefore necessary to conform to strict inclusion/exclusion criteria in order to make 
the groups as similar as possible regarding known prognostic characteristics and to 
allow comparability between them. 
Pre- and post-test studies 
Other studies examine subjects before and after treatment, measuring any improve-
ment. The issue of whether a possible outcome can be ascribed to the treatment is 
of great significance here, however, as confounding factors are more likely to occur 
when 'time' is taken into account. 
Retrospective studies 
This evaluation model examines data on groups of subjects submitted to different 
past treatments. The main advantage is that a large number of subjects can be con-
sidered over a greater timescale and geographical spread. 
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The main disadvantage, however, is that, as the events have already taken place, a 
number of essential data elements can be missing. These may include: 
the standardisation of therapeutic protocols; 
the definition of inclusion criteria; 
the accuracy and completeness of individual data related to the prognosis; 
the standardisation of outcome measures; 
the evaluation of all subjects, including drop-outs; and 
the effects of unforeseen confounding factors. 
Case-control studies 
The most frequent application of case-control studies is when a causal relationship 
between etiological and protective factors is being examined. Usually the 'cases' are 
subjects displaying the factor being examined, while the 'controls' are subjects with-
out this condition. 
Case studies 
Finally, studies can be carried out with no control, examining only those subjects 
admitted to the treatment under evaluation. As such a study cannot compare the 
treatment to any other, its main application is to develop new hypotheses about 
treatment and outcomes. 
Conclusions 
The randomised control trial seems to be the best choice for assessing drug treat-
ment, both because of its methodological aspects and because of the reliability of its 
results. 
Nevertheless, even control studies face a number of operational difficulties: 
• the difficulty inherent in defining and standardising objective methods which can 
be applied across the different professions involved for describing and assessing 
client characteristics; 
• the impossibility of controlling factors not covered by the protocol, but which 
can still modify the subject's condition and its evolution over time; and 
• the low level of statistical and epidemiological competence among professionals 
working in the field. 
Any future improvement in the quality of drug treatment in Europe must, therefore, 
rest on further evaluation research. Improving epidemiological and statistical com-
petence among drug professionals can also be seen as a positive step. The 
European Monitoring Centre for Drugs and Drug Addiction can play a major role 
in facilitating study design and the statistical analysis of epidemiological data, 
both of which are essential for the future of effective treatment. 
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APPLYING ECONOMIC EVALUATION 
IN THE SUBSTANCE-MISUSE FIELD 
Evi Hatziandreou 
The constant battle between competing needs for society's scarce health-care and 
social resources is clear for all to see. These resources are not, however, only financial: 
people, facilities, equipment, time and even knowledge are all finite, and alternative 
uses for them can be found both within and without the health-care sector. This sit-
uation dictates that choices need to be made as to how best to use resources. 
In economics, this is the notion of 'opportunity cost' - the value of the best alterna-
tive which is foregone because the resources available were used for other purposes. 
In other words, the real cost of any programme is not simply its budget, but also the 
health and social outcomes that have not been achieved by some other programme 
because resources have been devoted to another project. Society's goal is to max-
imise the total benefits (health, social, etc.) of these finite resources. Efficiency is 
achieved when a given amount of available resources produces as much 'effective-
ness' or benefit as possible or, alternatively, when a specified goal is achieved at the 
lowest cost. The desire for efficiency is the driving force behind economic evalua-
tion. This scientific discipline is of the utmost relevance to health and social 
decision-making at all levels, as it provides the necessary economic and social data 
for informed decisions to be made. In recent years, the importance of economic 
evaluation has been strengthened by the competitive marketplace, the demand for 
accountability, the desire to assess the return on investments and the need to allo-
cate resources as wisely as possible. 
Economic evaluation identifies, measures, values and compares the costs and conse-
quences of alternative uses of finite resources (Drummond ef al., 1987). It examines in 
an organised, systematic and explicit way all the factors involved in a decision to 
commit resources to one form of action rather than another. In this way, it deals explic-
itly with the issue of 'choice'. Therefore, if treatment is to achieve its potential, so too 
must economic evaluation. This chapter introduces the key concepts involved and 
illustrates the uses to which economic evaluation can - and must - be put. 
Definitions 
According to Drummond ef al. (1987), two fundamental and interdependent ques-
tions face decision-makers and funders: 
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• Is it worthwhile allocating scarce resources to a health procedure, service, pro-
gramme or intervention? 
• Could the resources thus allocated be spent more productively? 
Economic evaluation can help to answer these questions. It is a structured, system-
atic, comprehensive and explicit process which establishes the context of the prob-
lem, lays out the alternatives, predicts the consequences of each alternative, values 
the expected outcomes and calculates their total costs and benefits. 
In the health sector, this is accomplished by determining the total value of a specific pro-
gramme. The value of improved health is reflected in a number of ways. Better health 
reduces the need for health care and conserves resources. It increases productivity by 
lowering absenteeism and improving worker output. It also has the inherent value of 
influencing the length and quality of an individual's life. But for the decision-maker, its 
main value is its ability to improve the consistency and quality of decision-making. 
Rationale for economic evaluation 
Drummond ef al. (1987)'s two general questions can form the basis for the issues 
covered by economic evaluation: 
• can this intervention work - a question of 'efficacy'; 
• does this intervention work - a question of 'effectiveness'; and 
• does this intervention reach those who need it - a question of 'availability'. 
As the other chapters in this monograph show, the distinction between 'efficacy' and 
'effectiveness' is key to evaluation. The former assesses the likelihood of the benefit 
to individuals in a defined population as a result of a specific intervention applied 
to a given health or social problem under ideal conditions. The latter refers to the 
expected outcomes under realistic conditions. 
The availability of - and access to - an intervention is also a matter for economic eval-
uation (Plotnick, 1994). It is important to consider how 'costs' and 'benefits' (or social 
gains and losses) are distributed among the different sections of society, just as it is 
important to understand from whose perspective the costs and benefits are examined. 
If this societal view is adopted, all the significant costs and benefits that flow from the 
intervention are taken into account, regardless of who is experiencing them. 
Costs and health benefits 
Costs are defined as the economic resources used to provide a service. There are 
three categories of cost: 
• direct costs, which measure the value of resources directly consumed. These 
costs can be health- and/or non-health-related; 
• indirect costs, which reflect the value of lost or reduced productivity due to pre-
mature mortality or morbidity; and 
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• intangible costs, the hardest to measure, related to the suffering, stress and isola-
tion of those in ill health (in this case, drug dependence). 
The major components of substance misuse costs are (French ef al., 1991 ; Plotnick, 1994): 
• health-care costs; 
• criminal-justice costs; 
• social-service costs; and 
• other hidden costs, such as those resulting from aversive behaviour (the installa-
tion of security systems, for example) and personal and psychological costs. 
Health benefits may take many forms, for example: prolonged life; improved func-
tioning and activity; relief from pain and anxiety; greater capacity to work and earn; 
reduced medical-care expenses; and enhanced quality of life. 
Types of economic evaluation 
Economic evaluation encompasses different analytical approaches with some com-
mon methodological features (Drummond ef al., 1987): those that only measure 
costs; and those that measure both costs and health benefits. A third category mea-
sures health-related quality of life but is not discussed here. 
Cost-only approaches 
Cost of Illness (COI) studies are descriptive and aim to enumerate all the costs related 
to a specific disease or condition (whether asthma, cardiovascular disease, sub-
stance misuse, etc.) in the population in question. They therefore estimate the total 
economic burden on society of a condition, as opposed to the costs of a specific 
intervention. No comparison of alternative interventions is involved. COI studies fol-
low either a prevalence-based or incidence-based approach: the former estimates 
costs for a base year; the latter estimates lifetime costs associated with the condition. 
Cost Minimisation Analysis (CMA) is used when the interventions being evaluated 
produce similar outcomes, sharing the same effectiveness. The least costly alternative 
is then identified by comparing the total costs of each. This is the simplest form of 
socio-economic analysis (Luce and Elixhauser, 1990), but it is important for this 
equivalence to be rigorously documented if a CMA is to be justified. 
Cost-benefit approaches 
A number of methodologies allow interventions which have differential outcomes to 
be compared. These methodologies differ, essentially, in the manner in which the 
benefits are measured. Obviously, for such studies to work, the expected differential 
benefits from alternative uses of available resources need to be known. 
Cost-Benefit Analysis (CBA) enumerates and compares the costs and benefits of a 
particular intervention. Its distinguishing feature is that both costs and benefits are 
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measured in monetary terms. This approach attempts to determine whether an inter-
vention's expenditure is greater or lower than its expected benefits, also measured 
financially. The cost-benefit ratio, which calculates benefit minus cost, is then used 
to evaluate the intervention - if the ratio is positive, then society is better off 
devoting resources to that particular intervention. 
In contrast, Cost-Effectiveness Analysis (CEA) does not convert health and social out-
comes into monetary units. This is particularly appropriate when monetary values for 
the principal benefits are not quantifiable or are controversial. In contrast, CEA 
quantifies these benefits in the most appropriate health or physical units, such as 
days of morbidity averted, the number of cases prevented or years of life saved. 
Treatment-related benefits could include the number of abstinent incidents over time 
or a specific reduction in drug use or crime. At the end of this process, a cost-
effectiveness ratio is calculated, being the cost per specified health-effectiveness unit. 
CEA can therefore depict the trade-offs involved when choosing between different 
interventions or variations of an intervention, although only interventions with out-
comes measured in equivalent units can be compared (Gold et al., 1996). 
Similarly, Cost-Utility Analysis (CUA) compares two or more interventions, measur-
ing costs in monetary terms, but also considering benefits in terms of quality or util-
ity (Luce and Elixhauser, 1990). CUA does not simply enumerate these benefits as 
'years of life saved', but uses a broader analytical framework. Unlike CEA, only one 
outcome measure, the 'quality-adjusted life years' (QALYs), allows interventions 
with non-equivalent outcome units to be compared. 
Economic evaluation in drug treatment 
Despite the fact that resources have traditionally been scarce, and although 
economic evaluation is an irreplaceable tool when seeking to maximise collective 
benefits, it has rarely been applied systematically to the drug-treatment field. There 
are a number of notable exceptions, however. 
Cosf of Illness 
Over the past 20 years, numerous studies have assessed the economic costs of drug 
misuse. According to various researchers (French ef al., 1991 ; President's Commission 
on Model State Drug Laws, 1993), these studies have significantly underestimated the 
true burden on society by failing to consider tangible expenses that affect the drug 
user, the environment and society at large. These sums may include falling property 
values in drug-using communities, the real and opportunity costs of drug-education 
programmes and the financial effects of complications related to secondary disease. 
Similarly, because of the difficulty and controversy surrounding the methods used to 
measure intangible costs, these have rarely been included. 
A distinct feature of the costs of drug misuse (as opposed to those of alcohol misuse 
and mental illness) is the high proportion, up to 74% in some studies, of crime-related 
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expenses (Rice ef al., 1991). This is strong evidence that society, and not the indi-
vidual, bears the burden of the economic consequences of drug misuse. It is also 
worthwhile noting the observation of researchers at Rutgers University (President's 
Commission on Model State Drug Laws, 1993) that, while up to 4 1 % of the total cost 
of illness is borne directly by treatment and treatment-support services in the mental-
health field, less than 5% of drug-misuse expenditure is borne by addiction treatment. 
COI studies and methodologies have improved (see French and colleagues, 1996). 
This provides a comprehensive conceptual framework to help researchers more 
accurately estimate the social costs of drug misuse. The process is made more uni-
form by capturing tangible and intangible costs that were previously left out. 
The first step of this framework calls for categorising the adverse health and non-
health consequences of drug misuse into one of three classes: physical-health prob-
lems; mental-health problems; and social problems. The second step identifies and 
classifies the associated costs by their bearer. Finally, methods to estimate each of 
the social-cost components need to be selected and developed. 
Cost-Benefit and Cost-Effectiveness Analysis 
COI studies can estimate the aggregate monetary burden to society of the health and 
social effects of drug misuse. Inherently, however, they do not contain information 
that decision-makers can use to assist them in resource allocation. This is the domain 
of CBAand CEA. 
Relatively few CBA and CEA studies have been conducted in the drug-treatment field. 
In a critical assessment of the existing literature, Apsler (1991) claims that there is no 
single and straightforward answer to the question: 'Are today's drug-treatment pro-
grammes cost-effective?' According to Cartwright and Kaple (1991), not only are 
some treatment programmes of 'questionable' cost-effectiveness, some are even 'cost-
ineffective'. Underlying this lack of clarity is perhaps a lack of rigour in research 
design and implementation. 
Recent methodological improvements do, however, parallel those in COI studies. A 
particularly interesting and relevant example is the work carried out, again, by French 
and colleagues (1996). These researchers developed a simple methodology to estimate 
the health-related costs of drug misuse based on a rigorous theoretical foundation. 
They used an integrated approach combining medicine, epidemiology, economics and 
psychology, aimed at a target group of policy analysts, evaluators and researchers. 
The technique developed uses QALYs to estimate the value of avoiding drug-related 
morbidity and mortality. The methodology is then tested by estimating the value of avoid-
ing sexually transmitted diseases, hypertension, bacterial pneumonia and tuberculosis in 
a 32-year-old white American male. It is also important to mention Hser and Anglin's 
recommendation to use more sophisticated techniques, such as time-series analysis and 
advanced modelling, when assessing treatment impact (Hser and Anglin, 1991). 
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Overall, despite the lack of rigorous CBA or CEA studies, those available demon-
strate that the benefits of treatment seem to be at least as great as the respective costs. 
Clearly, however, this evidence needs to be strengthened by further appropriately 
designed and conducted economic evaluations. 
Methodological challenges 
Economic evaluation is not an easy area for researchers. A plethora of obstacles and 
hurdles need to be overcome, especially as evidence of 'effectiveness' is more 
difficult to measure than 'cost'. Assigning an observed effect to treatment, the bias 
inherent in selection and self-selection, and the relative weakness of the evidence 
(contrasting, for example, with the role of drug-use careers) all pose formidable 
challenges. Apsler (1991) summarises these challenges as follows: 
conceptual problems; 
disagreement about treatment goals; 
disagreement about outcomes; 
duration of treatment; 
existing variability among different interventions; 
high drop-out rates; and 
an over-reliance on self-reports. 
More 'manageable' difficulties include multidimensional and time-related conse-
quences, as well as the problems associated with assigning monetary value to costs 
or benefits. Finally, the relevance of any results to untreated populations remains a 
dilemma that cannot be easily ignored. 
To address these challenges, Apsler (1991 ) notes the importance of developing some 
form of standard methodology or guidelines. This could include establishing a work-
ing definition of treatment goals and deriving appropriate outcome measures from 
them. He also recommends developing a comprehensive set of objective measures 
for assessing outcomes. 
Complementary activities have also been proposed to catalyse integrating economic 
evaluation into programme evaluation. These include educating decision-makers 
about economic evaluation, its purpose, nature, strengths and limitations. 
Furthermore, early exposure to the principles of economic evaluation should be 
encouraged for social scientists. 
Ultimately, the burden of evidence is growing heavier. Policy-making now requires 
information and a sound understanding not only of the nature and magnitude of the 
real consequences of drug misuse, but also of the cost and effectiveness of alterna-
tive interventions, so as better to allocate resources. Economic evaluation can 
provide this and, in so doing, can make the decision process more explicit and 
transparent. But, if it is to do so, more sophisticated techniques and approaches 
urgently need to be developed. 
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INTRODUCTION 
W einrich Küfner begins this section by outlining how the principles of treat-ment evaluation can be applied in practice. In particular, he explores the barriers to the effective use of evaluation findings in the clinical setting, a 
situation that leaves the question 'what works?' unanswered. Küfner's suggestions for 
making evaluation relevant to the practitioner include setting research standards and 
classifying research designs. He also recommends systems theory as a way of 
rooting evaluation in the practitioner's experience of working with drug users. 
Umberto Nizzoli then illustrates how evaluation can be applied on the ground. 
Drawing on his experience developing an information system in the Emilia-
Romagna region of Italy, he underlines the obstacles to strategic development, 
among them the lack of shared evaluation goals, opposition to the concept of 
evaluation, and never-ending discussions about the usefulness or otherwise of eval-
uating particular projects. Nizzoli goes on to describe how Emilia-Romagna 
developed its own evaluation instrument, TedEval, and how similar systems are 
being developed throughout Europe via inter- and intra-sectoral communication. 
In the final chapter of this section, Michael Gossop and the National Treatment 
Outcome Research Study (NTORS) team detail how a treatment-evaluation system 
was set up in the UK, and describe the Maudsley Addiction Profile, an evaluation 
instrument developed specifically for NTORS. The Study now plays an important role 
in developing and guiding British drug-treatment policy responses. Its initial findings 
have provided the evidence that treating drug problems can reduce harm both to 
individuals and to society as a whole. These findings have also been used by the UK 
Department of Health to formulate guidance for treatment purchasers. 
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CHAPTER 6 
USING EVALUATION RESULTS 
IN TREATING DRUG ADDICTION 
Heinrich Küfner 
The influence of evaluation research on treating drug addiction seems to be very 
limited. Whether, given the current state of evaluation research, it is desirable that 
research findings should have a stronger influence on the field or not requires more 
detailed consideration. There are many good reasons, on both the research and clin-
ical sides, why the influence is not very great. 
Problems and limitations of evaluation research 
External validity 
Outcome research often has a low external validity, meaning that any generalisation 
of results to other patient samples and treatment settings should be undertaken very 
cautiously. Patient samples should be representative for the population being 
assessed and statements about influence variables restricted to categories of those 
variables assessed in the studies. Figure 1 demonstrates the problem of assessing 
influence variables with insufficient variations. 
Figure 1 : Treatment length and outcome in residential treatment 
Studies 
All studies 
Germany 
Other countries 
Abstinence 
rank correlation 
(n studies) 
0.35 (38) 
0.50(10) 
0.12 (28) 
Improved 
rank correlation 
(n studies) 
0.14(40) 
0.33 (10) 
0.03 (30) 
Source: Süß (1995) 
In alcoholism research, Anglo-Saxon researchers have found no relationship 
between length of treatment and outcome (Miller ef al., 1995). A meta-analytic 
study including investigations about alcoholism treatment in Germany (Süß, 1995) 
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demonstrated a low, but significant association between treatment length and 
positive outcome (r = 0.35). In German outcome studies, with their much longer 
treatment length, there was a substantial association of outcome with treatment 
length with a rank correlation coefficient of r = 0.52. 
But excluding these German studies, Anglo-Saxon research found no significant 
relationship between the two as only treatments of less than 4-6 months' duration 
were studied. Thus, treatment length as a variable was not represented in the full 
range of clinically relevant variations. Significant relationships between outcome 
and treatment length cannot be proved purely by short-term treatment. Therefore, 
generalisation of these studies is restricted. 
As for patient samples, the scientific ideal is that of a randomised control study. But, 
as has already been argued in previous chapters, such studies are not necessarily 
without bias - only patients who are will ing to undergo any of the treatments on 
offer can be enrolled in the sample. In reality, substantial groups of patients are not 
will ing to participate in the treatment alternatives being provided. 
Internal validity 
Another major problem with evaluation is that the results of outcome research are 
seldom clear, allowing instead for multiple interpretations. As a result, not only exter-
nal but also internal validity may be insufficient. For example, there may be several 
competing causal explanations and interpretations for the results of an evaluation. In 
statistical terms, a low rate of explained variance of an outcome variable indicates 
the likelihood of many unknown influences. Furthermore, if the results are not 
conclusive it is hardly reasonable to draw far-reaching conclusions. 
Discrepancies in results 
Different studies into the same issue often do not produce similar results. It is thus 
unwise to rely on a single study. In the case of such discrepancies, the task facing 
researchers is to explain and accept the differences. 
One option is to carry out meta-analyses as a quantitative method of summarising 
evaluation results. Although there may not always be a sufficient number of studies 
for meta-analyses, if several investigations concerning a particular variable do exist, 
meta-analysis is the best quantitative way to summarise the evaluation results 
(Durlake and Lipsey, 1991; Cartwright and Kaple, 1991). While meta-analysis does 
have several drawbacks, such as merging the results of studies carried out under dif-
ferent conditions, it can give more valid results than narrative reviews. 
One condition for such an analysis is the existence of enough studies with corre-
sponding outcome criteria. This may, however, prove problematic in the field of drug 
addiction. To date, as far as this author is aware, no meta-analytic study has been pub-
lished into catamnestic treatment outcome in illegal drug addiction, although two 
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reviews are in progress (one in the framework of the IPTRP project, co-ordinated by 
Kaplan and colleagues, and one by Prendergast, Podus and Chang, 1998). Several 
questions remain open about the methods of meta-analysis, but overall this 
approach would improve the present status of outcome research. 
Insufficient differentiated outcome 
In most cases, outcome research relates to global outcome criteria, for example to 
the categories 'improved' or 'unimproved' in relation to drug consumption and other 
such factors. Outcome is seldom related in a multivariate way to client or treatment 
characteristics and to external circumstances applying multivariate statistical tools. 
On the other hand, the clinical tasks of diagnosis and treatment are tailored to a 
large extent to the patient's individual situation with its many influencing and 
confounding factors. These create many questions that cannot be answered by 
global outcome studies. To bridge the gap between clinical tasks and the scientific 
approach of evaluation is thus a continuous problem. 
Divergent aims and interests 
Evaluation research is often fragmented. Clinicians, for example, are more inter-
ested in the effect of individual treatment components - so that they can be added 
to or removed from existing treatment programmes - than in the total treatment 
package. To plan such studies over a longer time period, however, requires close 
co-operation between researchers and clinicians. Evaluation has to be applied as 
part of a clear strategy, for example, to improve a single treatment system or to 
improve a treatment system in a specific region or country. Despite the different 
political interests in evaluation results, the scientific criteria of reproducibility and 
objectivity have to be fulfilled. 
Feedback to practitioners 
A final issue is that there is all too often a long delay between data analysis and 
feedback to the clinicians, which can invalidate the research. If data are to be 
relevant for clinical decisions, for example a patient profile on the European 
Addiction Severity Index (EuropASI), they have to be fed back quickly. While this 
is never easy in the research field, the hardware and software are now available to 
facilitate this task. 
Improving evaluation research 
Besides these difficulties and limitations, it should be emphasised that there is no 
alternative to evaluation. There are, however, many opportunities for improving the 
situation. 
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First and foremost, it is essential to set research standards or to suggest solutions for 
methodological problems in treatment evaluation. Some ideas have already been 
proposed, for example in the National Institute on Drug Abuse Monograph series 
(Cazares and Beatty, 1994; Kolbey and Asghar, 1992) or by the German Association 
of Addiction Research and Treatment (Deutsche Gesellschaft für Suchtforschung und 
Suchttherapie e.V., 1994), but as far as this author knows, no European standards are 
yet available for illegal drugs. 
Evaluation standards have only been actively developed in the prevention field 
(EMCDDA, 1998b), but there are clearly areas where common standards are 
required for evaluating outcome. For instance, many studies examine drug use only 
during the 30 days before the treatment is assessed. But is this really relevant for clin-
ical purposes? Under what circumstances is a reduction in the number of days on 
which drugs are used an improvement - or is the wrong variable being measured? 
Clear notions about what criteria and what differences are really clinically relevant 
need to be developed. 
Second, the research design should be clarified to improve its chances of producing 
clinically significant findings. The statistical power of the planned patient samples to 
detect a given difference in the outcome criterion of two treatments should be exam-
ined. The prerequisite is to estimate the true difference between treatment effects 
which is not usually known. Computer programmes are available to calculate such 
statistical power, such as 'Sample Power' in SPSS. 
In pharmacological treatment, the ideal design is a placebo-controlled double-blind 
randomised study design, but in psychosocial treatment the situation is more 
complex. As for the methodological aspects of evaluation, the global aim is to control 
prospectively as many alternative influence variables as possible. In multi-site studies 
with large patient samples many such variables can be controlled in statistical analyses 
and the danger of unknown influence factors seems to be reduced, but, of course, 
not ruled out. The chances of natural studies producing meaningful findings without 
randomised treatment samples should be emphasised because in many cases it is not 
possible to randomise patients to different treatments. 
Third, as mentioned above, meta-analytic studies provide more reliable and valid 
results than single studies and so should be carried out for different areas of interest. 
It would even be a step forward simply to count the number of studies with positive 
effects and those with no discernible or with negative effects. In the alcoholism field, 
Miller ef al. (1995) demonstrated a very high correlation of 0.98 between this 
simple method and a complex index weighting the results according to qualitative 
criteria. 
Finally, it seems necessary to develop complex models and theories, because reality 
does not consist of only two variables, one dependent and one independent. The 
literature reveals several models applying path analysis and structural equation models 
to the development of drug addiction (Taylor and Young, 1997). As a first step, any 
such models should be constructed as structural models (with knots or boxes as 
variables) closely related to empirical findings, but without structural equations. 
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Such mathematical functions are allocated to the variables in a second step 
followed by empirical analysis (e.g., by means of Linear Structural Relationship 
Analysis or LISREL) as a third step. 
Systems theory and visualising techniques for developing models 
Systems theory, not to be confused with systemic treatment, could provide the basis 
for model construction. It is a broad approach characterised by the following simple 
principles: 
• A system is characterised by a number of aims or functions: a pile of sand is not 
a system unless it is a model for a landscape on a distinct scale. But a chair can 
be seen as a system: it has a function for the person sitting on it. 
• A system is made up of a number of interconnected elements or subsystems. 
• A system has a border to other systems. Thus the object's environment and affect 
on other objects around it need to be assessed. 
Well-known principles of systems theory include the terms 'feedback' and 'regulation-
system' to hold constant a variable such as the temperature in a room or the sugar 
level in the blood circulation system. Systems theory has several branches: 
• general systems theory; 
• cybernetics; 
• black-box theory (Bischof, 1995); and 
• simulation techniques for dynamic systems (Liebrand et ai, 1998). 
Visualising techniques are helpful tools for describing systems, their elements and 
relationships. At least two different notation systems can be distinguished (Küfner 
1996, 1998): 
• Within black-box analysis, arrows represent variables as input into or output from 
boxes. These boxes connect the input and output variables rather as rules or 
mathematical functions. 
• Alternatively, and more important for structural equation models, arrows may 
mean only the influence of a variable represented as a knot (or box) to other knots 
or variables. 
In another type of model describing the process of change, arrows symbolise a 
sequence of two time points related to the same variable without a causal relation-
ship. An illustration of a graph model is given in Figure 2 below. Sometimes the dif-
ferent meanings of arrows, boxes and knots in diagrams are confusing and should be 
avoided. In structural equation models, knots or circles symbolise hypothetical 
constructs, which are assessed by operationalised variables. 
In black-box analysis, influencing factors are analysed without knowing how the 
construct - for example, self-efficacy - is realised in the central nervous system. It 
may also be helpful to ask how the variables and their connecting boxes are realised 
in the biological system, leading to creative associations between psychosocial and 
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Figure 2: Graph model of drug abuse 
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biological perspectives. In the long term, an individual addiction model has to be 
based on biological systems, but without being reduced to biological processes. 
Principles of systems theory should thus be combined with the development of a 
structural model - the first step in path analysis and in creating a structural equation 
model. Combining systems theory with computer-simulation techniques may also be 
beneficial. Such combinations could become powerful and useful tools in developing 
and testing models. 
Strengths and shortcomings 
In treatment settings, clinicians have to undertake concrete tasks to help patients to 
cope with their situation and to motivate them to change their unsuccessful behaviour. 
While clinicians thus know the problems inherent in treating individual cases better 
than researchers do, they are often too close to the patient and have problems formu-
lating broader research questions not connected to the individual situation. If clini-
cians are interested in research findings and theoretical concepts they will also know 
the problems of applying those results to the individual case better than many 
researchers. The task here is not to comment on theoretical constructs such as moti-
vation, but to aid evaluation research. 
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Clinicians tend to have limited knowledge about the principles of empirical research 
and research methodology. A simple overview of different types of evaluation can 
therefore help to differentiate the broad range of possible evaluation approaches. 
Evaluation studies may examine the implementation of a programme, global and 
differential treatment outcomes, meta-analysis and cost-benefit analyses (Cartwright 
and Kaple, 1991 ). If clinicians understand these different types of evaluation - their 
benefits as well as their limitations - they wil l better understand the methods and 
results of empirical studies. One bridge between clinicians and researchers that still 
needs to be crossed is to define the standards of knowledge. 
To ensure good-quality treatment, 'quality-control' measures are now being estab-
lished in the addiction field. In Germany, this approach has been promoted primarily 
by health and pensions insurance companies, and only to a secondary degree by the 
treatment centres themselves. 
Evaluation is a routine part of quality-control programmes and aims to discuss basic 
data within quality-control groups before deciding whether or not to make any 
changes in the treatment. Evaluation research should form the basis for evaluation 
procedures within quality-control measures. There is, therefore, a need to distinguish 
between quality control and evaluation research. 
Figure 3: Overview of different forms of evaluation 
1. Implementation: 
is the treatment programme feasible? Is its structure adequate for patients? 
2. Global outcome (during treatment and at follow-up) 
3. Treatment process interventions and patient behaviour: 
changes in patient variables 
4. Differential outcome I: 
patient factors influencing outcome (patient variables as predictors) 
5. Differential outcome II: 
treatment factors (as predictors) and outcome 
6. Differential indication: 
interaction of patient and treatment variables 
7. Meta-analysis of results in the literature 
6. Cost-benefit study 
Often, social trends are more influential than the results of evaluation studies. If no 
evaluation results are available, then interpretations and modern trends become the 
basis and background for deciding treatment characteristics. For example, treating 
male and female drug addicts together in one facility is not based on empirical find-
ings, but on social trends. Indeed, some empirical results actually show that 
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separate treatments for men and women produce better outcomes, at least for 
alcoholics (Küfner and Feuerlein, 1989). 
Evaluation results and consequences 
The treatment of drug addicts is working, but not very successfully. An indication of 
this is that the drop-out rates are frequently very high. In Germany, for example, about 
70% of those undergoing in-patient drug-free rehabilitation terminate their treatment 
prematurely. In the literature, the drop-out rate is the strongest predictor 
(r = 0.3) of negative treatment outcome (Roch ef al., 1992). 
Likewise, the drop-out rate at a rehabilitation centre is an indicator of its treatment 
outcome with the advantage that it can be assessed within the treatment period with-
out a cost-load catamnestic study. Clinicians and researchers may therefore focus on 
reducing the number of drop-outs and increasing time in treatment. 
One new approach to reducing drop-out rates is a community-oriented treatment 
project in Germany based at a farm and involving minimal treatment (Vogt et al., 
1995). Compared to the usual treatment with methadone or to in-patient rehabilita-
tion this approach focuses on a new and totally different social environment with no 
illegal drugs and with no other clients present. Treatment is carried out as a coun-
selling process between the individual client and the farmer's family. Since the influ-
ence of traditional psychotherapies on drug addicts is very limited, other forms of 
psychosocial influence could be helpful. Clinically oriented researchers could help 
identify different psychosocial approaches in a more systematic way. 
At the same time, there should be a link to the pharmacological treatment 
approach. Presumably, both approaches are necessary and a combination of the 
two is probably more successful than a single approach (Ball and Ross, 1991). 
Analysing both psychosocial and pharmacological treatment evaluation research is 
thus indispensable. 
Indication 
One complex issue for clinicians that could benefit from research is that of indica-
tion. The empirical findings regarding indication in the field of drug addiction are, 
however, very poor, with, perhaps, one exception. Unlike with alcoholism, there is 
a widely accepted positive relationship between drug-treatment length and out-
come. As to indication, McLellan (McLellan and Alterman, 1991) and others have 
shown that addicts suffering from the most severe problems achieve better results in 
longer-term treatments. This is not a very concrete strategy for indication, but it does 
demonstrate an empirical tendency. 
Indication is not only a task of empirical evaluation research, and other aspects, such 
as costs, are equally important. Even without empirical knowledge about the differ-
ential effects of various treatments an indication strategy can be established. 
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The first indication strategy, in the case of no empirical findings about differential 
effects, is to apply minimal treatment. If this is not successful, the next intensive 
intervention should be applied. 
The second strategy is always to apply the treatment that gives the best results. But 
in this case, the prerequisite is for an optimal treatment concept for all patients, 
which currently does not exist. It would thus be very unrealistic to attempt to apply 
this strategy. In cases which are not clear-cut, the tendency is to choose what is 
considered the best kind of treatment, whether or not this is really true, excluding 
cost aspects. Being certain of success seems to be more important than expense in 
this strategy. 
The third indication strategy is oriented to the patients' special needs. If the patient has 
a problem in addition to the drug addiction - for example, a phobic disturbance - then 
additional treatment should be specified. This would seem to be a practical approach, 
if there are not too many additional disturbances requiring special treatment. The task 
of evaluation would be to show that this indicative treatment approach is more suc-
cessful than a homogenous treatment concept for all drug addicts. 
Finally, a fourth indication strategy applies the empirical results of evaluation studies 
to the effects of patient variables - such as age, gender, personality, co-morbidity -
combined with treatment characteristics - for instance, treatment length, whether in-
patient or outpatient, family treatment, interactional-oriented treatment or more 
social-skills treatment. An example of this approach is the MATCH project, which 
recently published its first, not very encouraging results of matching alcohol-
dependent patients with treatment strategies (MATCH Research Group, 1997). 
Considering these different strategies and the results of indication in evaluation 
studies, it can be said that evaluation studies and their results should be part of a 
more comprehensive approach or strategy for improving treatment. 
Conclusions 
The following suggestions could facilitate the transfer of information from research 
to clinical practice: 
• In order to use evaluation results in a more intensive way, quality-control 
programmes should be established. These should be distinguished from evalua-
tion research. 
• A manual for using the results of evaluation studies should improve basic 
knowledge about evaluation methods and can help to assess studies and their 
results. 
• By describing indication strategies it should be shown that empirical studies and 
their results may help to improve treatment if they are embedded in a compre-
hensive approach to optimise treatment. This means that clarifying the analysed 
treatment system and strategies are basic requirements for evaluation. 
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Meta-analytic studies can summarise the growing number of empirical results. 
Using visualising techniques to construct models and formulate hypotheses 
can help to provide an overview of the complex relationships of influence vari-
ables. 
Systems theory for planning studies and structuring results can also be used to 
clarify relationships. 
Developing structural and causal models can help to connect theoretical con-
structs, measurement variables and evaluation results. 
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T R E A T M E N T I N F O R M A T I O N SYSTEMS: 
T H E E M I L I A - R O M A G N A E X P E R I E N C E 
Umberto Nizzoli 
The situation regarding treatment information systems in Reggio Emilia at the end of 
the 1980s could have been replicated in numerous other towns across Europe. At the 
time, numerous clinical forms existed, either developed in isolation, adapted from 
existing ones or copied from other services. As patients moved around and informa-
tion was lost it became clear that such an ad hoc situation could not continue -
everyone in one specific region needed to use the same forms. 
In the Emilia area, articulating this need was a bottom-up process, which was 
accepted because the relationship between the health and social services and the 
regional government has always been a close one. At the same time, the Italian polit-
ical and institutional infrastructure was grounded in the concept of 'subsidiarity', 
meaning that many competencies and powers were transferred in the early 1990s 
from the state to the regions, until a national health policy had all but disappeared. 
Thus the Emilia-Romagna region, faced with taking responsibility for drug policy at 
regional level, needed as much reliable information on drug-treatment services and 
their clients as possible. A regional database form was thus developed to gather all 
possible information from drug misusers. The form was approved and all services 
operating in the region were obliged to use it. Since that time, no service has printed 
its own clinical forms. 
The regional form is computerised, and every service has been provided with the 
relevant hardware, software and training to use it. Each participating service also has 
its own database staff, co-ordinated by a network known as thé Observatory Group. 
As a result, the Emilia-Romagna region can now provide information about its 
service users that is unparalleled in Italy. 
Difficulties, however, still remain. As it is now some time since the forms were first 
developed, the problem has arisen of incorporating unforeseen data streams. As 
before, even in services long used to completing database forms, staff must also be 
constantly encouraged, reminded and cajoled to use them. Moreover, the forms are 
sometimes rejected at the service level itself. In one case, a service chose not to 
receive funds rather than comply with the terms and conditions of data delivery. 
This non-compliance is sometimes caused by unnecessary demands for data not 
included on the forms at state level. Some services, therefore, do not supply data to 
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the Departments of Internal Affairs or Health. Of Italy's 560 such services, only 
480-90 send their data to government departments. A final reason for the opposition 
to using the forms is that the region reserves the right to make the information 
provided public. For instance, it compares the services and draws up a 'league table' 
of the best and the worst. 
TedEval: a simple evaluation technique 
In the early 1990s, the region's Psychotherapy Group began to search for an instru-
ment which could be used to measure treatment effectiveness during a course of 
treatment rather than only at its end. The Addiction Severity Index (ASI) was deemed 
unsuitable, and other sources were examined in 1993 and 1994. From this extensive 
search, a unique instrument was created. 
First, treatment outcomes were defined, with consensus reached on the meaning of 
each and every one. Similar outcomes were grouped together, and a hierarchy 
drawn up. From this list, what was believed to be the most suitable database form 
was defined. The final result contained 20 items covering six areas of client obser-
vation: 
physical status; 
mental functioning; 
relationship status; 
social conditions; 
judicial status; and 
drug consumption. 
This instrument, called TedEval, describes the seriousness of the patient's status using 
a score from 0-1,000. It is designed for use at intake (usually after the third inter-
view) and should be repeated after six months to detect any possible changes. 
TedEval is confidential and reliable, and is also easy to complete (taking about seven 
minutes). As such, it is perfectly compatible with a service's clinical activities. The 
reading of the data contained within TedEval enables agency staff to consider the 
merits of the therapeutic strategy being applied. 
Although some practitioners argued for the production of a manual to accompany 
TedEval, none was produced, both for reasons of time and to give the practitioner 
the opportunity to make his or her own subjective interpretations. Guidelines were, 
however, provided on the use of the instrument. As virtually every service held a 
weekly meeting to discuss the clients' case histories, it was recommended that 
TedEval become a regular part of this meeting, allowing solutions to be defined that 
were best suited to the individual's needs. 
After a trial period of more than two years involving many hundreds of cases, TedEval 
has demonstrated itself to be a useful subjective indicator, with responsibility for its 
effectiveness ultimately lying with the group that uses it. As such, TedEval is a vital 
instrument in the weekly discussion that takes place in every operational group. 
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The Psychotherapy Group is researching the evolution of TedEval in 11 hospital 
centres, and a validation study is currently in progress. There is now a computerised 
TedEval which is even simpler to use, taking just 2-3 minutes to complete. An 
artificial-intelligence system of neural networks has been 'taught' to give a certain 
score to each answer for each item, and therefore provides an on-screen profile of 
the strengths and weaknesses of each patient. This computerised instrument can also 
give a final score from 0-1,000. The possible range of drug use has been divided into 
six stages: light use (under 180); medium-light (180-279); medium (280-479); 
medium-serious (480-599); serious (600-779); and very serious (780-1,000). 
Emilia-Romagna's evaluation system 
While Emilia-Romagna's Psychotherapy Group has been developing this evaluation 
instrument, the Observatory Group has co-ordinated the various related databases. 
Although the former group focuses on changes in the individual patient, the latter 
concentrates on the effectiveness of the regional service as a whole. As a conse-
quence, database items such as 'number of overdose deaths' or 'percentage of sero-
conversions' can become important indicators of the work carried out at regional 
level. 
The Observatory Group has developed a self-complete instrument to measure 
clients' consumption of various substances, the rationale being that a reduction in 
the level of drug use is thought to be the fundamental indicator motivating the exis-
tence of drug services and ensuring their effectiveness. The Italian version of the 
Nottingham Health Profile is also used to measure client well-being. 
These two questionnaires, in conjunction with TedEval (and another questionnaire 
on customer satisfaction developed by the Group of Warrantors), represent the 
treatment-evaluation package - weighted towards the 'client' as 'customer' -
currently used in Emilia-Romagna. 
ERIT: the multi-disciplinary and multi-national perspective of evaluation 
It can no longer be said that treatment evaluation in Europe is lacking. Of course, 
taking Europe as a whole, it is still scant, applied only by a minority of drug services. 
However, each EU Member State has undertaken important treatment-evaluation 
exercises and, although irregular, evaluation is increasing. Crucial to this development 
is the need for inter- and intra-sectoral communication. 
ERIT, the Federation of European Professionals Working in the Field of Drug Abuse, 
is just such a forum for communication and sharing evaluative experiences. Already, 
the Federation has collected some 20 different evaluation instruments which wil l 
soon be published to promote good practice. 
The key to all these instruments, whether large or small, is validation. Since many 
instruments have not been rigorously tested, an organisation like ERIT can provide a 
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'meta-validation' by comparing instruments. The goal of ERIT's evaluation project, 
therefore, is not to champion one particular instrument or to develop new tech-
niques; it is simply to synthesise (so as better to share) experiences. The project is 
also designed to spread the culture of evaluation, through monographs, seminars 
and conferences. 
One of the key issues identified through ERIT's evaluation work is the importance of 
the institutional, judicial and social contexts in which treatment evaluation is carried 
out. Not only does the meaning of evaluation derive from the context, but also the 
significance and scores attributed to that evaluation. This recognition should encour-
age a redoubling of efforts to work towards creating a social Europe, the 
fundamental condition for the spread of common evaluation instruments. 
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TREATMENT EVALUATION IN THE UK: 
THE NATIONAL TREATMENT 
OUTCOME RESEARCH STUDY 
Michael Gossop, John Marsden, Duncan Stewart, Petra Lehmann, Carolyn Edwards, 
Alison Wilson, Graham Segar 
The National Treatment Outcome Research Study (NTORS) is a large-scale, multi-
site, prospective study of treatment outcome conducted with a cohort of more than 
1,000 drug users who entered treatment services in England in 1995. The study was 
specifically commissioned by the UK government to provide evidence of the effec-
tiveness of existing drug-misuse treatment services. 
NTORS is the largest study of drug-treatment outcome ever conducted in the UK, 
although similar large-scale investigations have been conducted in the United States. 
These US studies include the Drug Abuse Reporting Program (DARP - Simpson and 
Sells, 1990), the Treatment Outcome Prospective Study (TOPS - Hubbard ef al., 
1989) and the 'six cities' research on methadone maintenance (Ball and Ross, 1991 ). 
Such research has demonstrated that treating drug problems can be effective. 
However, the difficulty of generalising from studies carried out in other countries is 
considerable as the characteristics of drug abuse and of drug abusers will differ in 
many respects from country to country, as wil l the types of treatment provided. 
Studies of the type and scale of NTORS are costly. They are expensive both in finan-
cial terms and in terms of the scientific and human resources required. They also rely 
on serious and sustained commitment from many individuals and organisations. 
Prospective outcome studies are, therefore, rare. It is partly for these reasons that no 
such investigation has previously been carried out in the UK. 
The further significance of NTORS is in part due to the fact that it has been 
designed and implemented as a national study, investigating treatment pro-
grammes from all over England. It is also a large-scale study with a comprehen-
sive design, looking in detail at the social and psychological characteristics of 
clients, as well as at a wide range of treatment operational factors in relation to 
multiple measures of treatment outcome. For these reasons, the results of NTORS 
wil l contribute to the scientific understanding of treatment outcome and wi l l pro-
vide valuable data about the impact of national treatment responses on drug prob-
lems. If the effectiveness of treatment interventions for drug problems is to be 
improved, policy-makers, researchers, service purchasers and providers all need 
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to have a clearer understanding of the many factors that contribute to the success 
or otherwise of treatment, so that drug services and interventions can be developed 
and strengthened. 
NTORS includes detailed and empirically based information about the pre-treatment 
behaviours, problems and social circumstances of the cohort, and the operational 
characteristics of the treatment programmes and interventions. As part of the research 
project, it wil l provide economic cost-estimates for the problems associated with drug 
abuse among the NTORS cohort. Most importantly, it wil l provide a detailed account 
of the impact of treatment in terms of the clinically significant psychological, social 
and behavioural changes that are observed. 
Research design and methodology 
NTORS monitors the progress of clients newly recruited into one of four treatment 
modalities: 
• specialist in-patient units; 
• residential rehabilitation services; 
• methadone-maintenance programmes; and 
• methadone-reduction programmes. 
The term 'modality' is used to refer to a broad category of treatment intervention. 
Within this category it is accepted that there may be some (possibly considerable) 
degree of variation. However, the treatment interventions included within each 
modality should have general defining characteristics and common features, such as 
the treatment setting within which the intervention is provided, the goals of treat-
ment or the types of procedures followed. 
The study's research design is based on a tradition of programme evaluation and 
longitudinal outcome research developed in the United States. It is naturalistic, and 
causal inference is achieved by measuring key variables and comparing treatment 
samples on the basis of pre- and post-treatment outcome measures. This design was 
chosen in preference to a randomised control design, as the client's own baseline 
measures in NTORS are used as a control condition to assess change. In a naturalistic 
or quasi-experimental design such as that employed in this case, pre-existing 
differences in client characteristics, as well as differences in social and envi-
ronmental circumstances, may explain some of the outcome variations across 
programmes. NTORS measures such differences so that they can be taken into 
account when examining which factors influenced what outcomes. 
Services of potential usefulness to NTORS were selected after considering: 
• the capacity of the specific agency and, in particular, its ability to recruit a suffi-
cient number of cases within the restricted time available - 'capacity' was 
defined in terms of the number of new cases presenting to the agency in the last 
month (at least 20 estimated new clients); and 
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• the location of the service - NTORS required agencies which were located 
throughout the health regions of England, but which were also based in areas 
with a representative prevalence of drug problems and drug-treatment services. 
A total of 54 agencies were selected: 
• 16 methadone-maintenance programmes; 
• 15 methadone-reduction programmes; 
• 15 residential rehabilitation services; and 
• eight specialist in-patient units. 
After participation in the project had been agreed, NTORS researchers visited all the 
agencies involved. The purpose of these visits was to familiarise and train drug work-
ers in the use of the Maudsley Addiction Profile (MAP) interview procedures (see 
below). Training manuals were also left at each agency for future reference. In addi-
tion, these visits allowed the necessary administrative procedures to be set up to 
ensure that agencies would be in regular contact with the two research bases 
(London and Manchester). Researchers encouraged a named individual at each 
agency to take responsibility for the on-site co-ordination of the project. Finally, 
these centres were provided with posters and leaflets to advertise the study to their 
clients. 
The Maudsley Addiction Profile 
The Maudsley Addiction Profile is a set of structured research interviews developed 
specifically for the NTORS project. The MAP profiles the social circumstances, key 
problems and experiences of drug users not only at entry into treatment, but also at 
the follow-up points during and after leaving treatment. The MAP interviews have 
been designed so that the key NTORS measures are repeatedly assessed during and 
after treatment, allowing the study to assess the impact of the particular treatment 
modality. The information needs of NTORS have been carefully balanced against the 
burden on staff time in interviewing clients, and so the MAP has been designed to 
be used by clinical and agency staff without formal research training. 
There were three stages to the MAP's development. 
• First, an initial pool of measures was compiled. These items included substance 
use and drug risk-taking behaviours, physical and psychological health, criminal 
involvement and social functioning (relationships, employment, education and 
training, etc.). A further set of measures was incorporated concerning the 
psychological aspects of drug use, motivation for treatment and coping strategies. 
These items may be useful for understanding the manner in which clients respond 
to treatment, as well as to longer-term recovery. 
• Second, draft versions of the MAP interviews were piloted with samples of drug 
users in several treatment services. This led to further refinements and improve-
ments in item structure and interview design, and two specific modifications 
were made. On the basis of the feedback from pilot interviews, a response-card 
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booklet was prepared to assist interview completion for each of the six MAP 
instruments. This has several benefits. It makes the interview quicker and easier 
to complete, enhancing interviewee attention. It also assists confidentiality in dif-
ferent settings since the respondent can read the number of an item rather than 
the item itself. Another design modification concerned questions about involve-
ment in criminal activity and with the criminal-justice system. Given the sensi-
tivity of this topic, the respondent was given the option of using a self-complete 
questionnaire for this section of the interview. 
• Third, a training strategy was implemented by the NTORS team to help agency 
staff administer the MAP interviews. Instruction manuals were prepared 
describing the rationale and structure of the interviews with detailed notes on 
the interview procedure and item completion. The research team then con-
ducted on-site training sessions for staff at each centre to ensure familiarity 
with the MAP. Subsequent feedback suggested that this procedure was valu-
able both as a specific learning exercise and for enhancing working links 
between NTORS and treatment staff. A pack of materials was prepared for 
each participating agency containing information for clients, consent forms, 
the MAP interviews and response cards, and enrolment forms. A single 'at-a-
glance' information sheet was also designed for the treatment staff, outlining 
the procedure to be followed for client enrolment and completion of the 
MAP-1 interview. 
The MAP-1 is a structured interview of about 45 minutes' duration. It has seven 
sections: 
background information; 
drug and alcohol use; 
change, motivation and coping; 
health; 
relationships; 
legal issues; and 
treatment. 
Six scales which have been used in previous research were selected and adapted to 
assess issues 2-7. A full description of the development of these measures is avail-
able from the authors. 
The MAP scales will facilitate comparison of NTORS data with previous research. 
Some new items were developed specifically for the study, particularly within the 
legal and treatment sections. The legal section of the MAP looks in detail at involve-
ment with the criminal-justice system and criminal activity. The treatment section 
records the client's treatment history and use of hospital, residential and community 
services for medical, psychological and substance-use problems. Successive MAP 
interviews administered during and after the index treatment episode comprise a 
core set of repeated measures from the above domains. 
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National treatment modalities 
The four types of treatment modality within NTORS included residential and out-
patient- or community-based treatments. The two residential treatments were spe-
cialist in-patient units and residential rehabilitation services. The two community or 
outpatient treatments were programmes providing either maintenance or reduction 
with methadone (or with other substitute drugs). 
In-patient units 
The UK's specialist in-patient drug-dependence units (DDUs) were established in the 
late 1960s, and in many respects the system is unique to that country. In-patient units 
are typically located within a psychiatric hospital and provide medically supervised 
detoxification coupled with counselling and support interventions. Usually, in-
patient programmes are staffed - and treatment delivered - by multidisciplinary 
teams, although psychiatric, medical and nursing staff are the most common mem-
bers of such teams. Programmes may vary in length from about two weeks to a 
maximum of three months, and there are relatively few specialist in-patient DDUs 
in the UK with this treatment approach. 
Residential rehabilitation 
Residential services include those run by a number of large national bodies. An 
important and influential recent development is the growth of Twelve-Step and 
Minnesota Model programmes, directed towards recovery through abstinence. 
Unlike the in-patient units, many residential programmes are located away from 
inner-city areas in order to provide a clear change of setting. Typically, abstinence is 
a treatment goal, although these programmes vary widely in terms of treatment phil-
osophy. In the UK, the four main types of residential rehabilitation are the Twelve-
Step programmes, Therapeutic Communities, Christian Houses and General Houses. 
Some residential projects manage detoxification directly, but most require addicts to 
be drug-free on admission. Treatment length varies from short-term with aftercare to 
long-term programmes of over one year. 
Methadone maintenance 
Since the establishment of UK drug clinics in the late 1960s, maintenance treatment 
has usually been delivered by specialist services, although more recently methadone 
treatment can also be delivered by General Practitioners, either independently or in 
association with a specialist drug agency - the so-called 'shared care' model. British 
methadone maintenance differs from the US model in that the methadone is often 
offered to the addict via a prescription which is taken to a retail chemist. The phar-
macist then dispenses the drug to the patient, which is typically consumed without 
supervision. The drug is prescribed from the outset on a stable-dose, non-reducing 
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basis. Following stabilisation at a suitable dose, the client may be maintained for 
either a fixed or an indefinite period. 
In addition to this traditional British method of prescribing maintenance drugs, in 
recent years there has been an increase in 'American-style' methadone maintenance 
in which clients attend a clinic each day and take their drugs under supervision. This 
has sometimes been referred to in the UK as 'structured methadone maintenance'. 
Eight such programmes were established as pilot projects by the Department of 
Health in 1995 and these programmes and their clients are included in NTORS. 
Methadone reduction 
Methadone-reduction programmes can be regarded as abstinence-oriented inter-
ventions and, where they provide short-term reduction within a period of less than 
6-8 weeks, they may also be regarded as detoxification programmes. Methadone-
reduction programmes are likely to vary in duration from periods of a few weeks to 
many months, possibly even years. Alterations may be made to the implementation 
of dose reductions or the duration of the treatment because of changed circum-
stances or crises presented by the client. In practice, many UK agencies operate a 
mixture of methadone-reduction and maintenance responses. 
NTORS clients and their problems 
Agency staff approached all eligible clients starting treatment between 27 February 
and 31 July 1995 and invited them to participate in NTORS. Clients were eligible for 
an intake interview providing that all the following criteria were met: 
• they were starting a new treatment episode; 
• they presented with a drug-related problem (other than alcohol); 
• they were able to provide an address in the UK for follow-up; and 
• they were not a previous client of NTORS. 
Overall, 1,110 eligible clients were recruited over the five-month period. Since 35 
did not provide sufficient locator information to allow follow-up, the sample base 
was revised down to 1,075. 
Table 1: Clients recruited into NTORS by treatment type 
Treatment type Number of clients recruited % of cohort 
In-patient 122 11.3 
Residential rehabilitation 286 26.6 
Methadone maintenance 458 42.6 
Methadone reduction 209 19.4 
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Table 2: Demographic profile at treatment entry 
Characteristic 
Male (%) 
Female (%) 
Mean age (years) 
White (%) 
In-patient 
(n = 122) 
77 
23 
30 
94 
Residential 
(n = 286) 
74 
26 
29 
88 
Methadone 
maintenance 
(n = 458) 
72 
28 
30 
90 
Methadone 
reduction 
(n = 209) 
73 
27 
27 
93 
The largest number of clients were recruited from the methadone-maintenance 
programmes. This was mainly due to the inclusion of the eight pilot structured 
methadone-maintenance projects within the NTORS framework, which contributed 
350 recruits to the study. 
At the point of entry to treatment, only 127 (11.8%) of the client group reported 
having a job, 89% had been unemployed in the previous three months and the 
majority (81%) reported being 'mostly unemployed' during the past two years. 
Most of the cohort were multiple or polydrug users. Few restricted their use to one 
drug, although dependence on heroin was the single most common drug problem, 
and the average length of heroin use for the cohort was nine years (s.d. = 5.8 years). 
The relative severity of the drug-abuse problems experienced by the NTORS clients 
must therefore be borne in mind when evaluating the impact of treatment. 
In the three-month period before starting NTORS treatment, there was frequent 
benzodiazepine use among the cohort. While approximately one in five clients were 
using benzodiazepines every day, a further one in six were using regularly each week 
and another one in six on an occasional basis. For some clients, benzodiazepine use 
will be licit, prescribed by a physician for a psychological disorder, and this 
prescription may or may not be misused by the patient. Others, particularly the occa-
sional users, were taking these drugs illicitly - particularly diazepam and temazepam. 
An important finding was that the frequency of crack cocaine use was higher than 
that of cocaine powder in every frequency-of-use category. Forty-nine people used 
crack every day in the three months before intake, a further 130 (12%) were regular 
weekly users and 199 reported using crack less than weekly. It was rare for the 
NTORS cohort to be daily users of cocaine powder: only 1 % used daily, although 
17% used on an occasional or weekly basis. 
Overall, 62% of the cohort reported that they had injected a drug in the three 
months prior to treatment. There were no statistically significant differences between 
men and women, nor between treatment modalities. The usual route of administra-
tion was intravenous for 59% of the clients who had used heroin in the three months 
prior to treatment, while 40% of heroin users smoked the drug. Cocaine powder and 
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amphetamines were also frequently injected - approximately half of those who had 
used these drugs in the previous three months had injected them. 
During the three months prior to treatment, 156 clients (14.5%) reported using a 
needle or syringe after someone else had used it, and there was a higher rate of pre-
treatment needle and syringe sharing amongst female drug users. This pattern of 
needle sharing has been observed in clinical populations and may indicate sharing 
between sexual partners. Sharing rates also differed significantly across treatment 
modality, with clients in residential treatment being more likely to report having 
used a needle or syringe after somebody else had done so. 
Shoplifting was the most commonly reported illegal activity, with more than one-third 
of the cohort having committed at least one such offence in the three months before 
intake. Fraud and burglary were also quite common, and more than one-quarter 
reported selling drugs. Almost three-quarters of the full cohort had been arrested in the 
two years before intake (again, most commonly for shoplifting, although about one-
third had been arrested for a drug offence). There were differences in the criminal-
activity profile of clients entering the various treatment modalities. 
Similar differences were found for treatment contact, although the treatment his-
tories typically reveal multiple help-seeking from different drug-treatment services. 
Rates of previous psychiatric treatment were highest for the residential and in-patient 
clients. A higher proportion of drug users entering the in-patient and residential 
modalities had received past hospital psychiatric treatment when compared to the 
community methadone programmes (in-patient: 14%; residential: 15%; methadone 
maintenance: 8%; methadone reduction: 6%). Clients in residential programmes 
were also more likely to have received community psychiatric treatment (21%) and 
to report receiving treatment from an Accident and Emergency department (64%). 
Current project status 
NTORS is still at a comparatively early stage. Analyses of the available six-month and 
12-month data are being conducted, and reports on both six- and 12-month outcome 
are currently in preparation. Initial results show substantial improvements in all the 
target problem behaviours immediately after starting treatment. Specific improve-
ments have been noted in the use of heroin and other illicit drugs, and there have also 
been reductions in injecting and needle sharing. Criminal behaviour has dropped and 
measures of physical and psychological health show further improvements. 
Summaries of these results are in the public domain (see Gossop et al., 1996, 1997). 
Preliminary analyses suggest that outcomes followed up after six months are likely 
to be broadly similar to those at the earlier follow-up point and to show substantial 
improvements in most key outcome measures. In particular, there are marked reduc-
tions in the use of illicit opiates including heroin, as well as in the use of other drugs, 
such as cocaine and amphetamines. These and other results became available in 
1997, although they were unavailable at the time of writing. Funding for NTORS wil l 
allow the clients to continue to be followed up into the next century. 
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n this final section, the impact of treatment evaluation on policy-makers (local, 
European and international) is discussed. 
In Chapter 9, Elfriede Koller draws upon her experiences co-ordinating drug policy 
at ministerial level in the German Länder. The lack of evaluation research is a source 
of frustration for policy- and decision-makers, leaving them open to the influence of 
'opinion-makers' rather than scientific evidence. With little or no comparative eval-
uation and no definition of what constitutes 'success', Koller argues, the financing of 
many treatment programmes relies on little more than goodwill and faith. Treatment 
evaluation and inter-sectoral co-operation and co-ordination are therefore vital if the 
correct decisions are to be made. 
In Chapter 10, Ambros Uchtenhagen provides an overview of the European Union's 
COST A-6 programme on treatment evaluation (Evaluation of Action against Drug 
Abuse in Europe). The programme's main objectives are to establish networks of 
researchers at national and international level, to collect and analyse relevant 
research material, to develop protocols and instruments for evaluation research and 
to stimulate international multi-site evaluation research. Over its five-year lifespan, 
the programme has developed the European Addiction Severity Index (EuropASI) 
evaluation instrument, as well as the Treatment Unit Form for gathering information 
on drug-treatment services. It has also reviewed the relevant European evaluation 
studies, the instruments and methodologies employed by those studies, and built a 
European network of scientists and professionals engaged in evaluation research so 
that information may be exchanged, workshops run and guidelines on treatment 
evaluation prepared. 
In Chapter 11, Maristela Monteiro describes the role of the World Health 
Organisation's Programme on Substance Abuse (WHO/PSA). Urging consideration 
for cost effectiveness, Monteiro argues for educating policy- and decision-makers -
as well as programme-managers - in the need for evaluation. An appreciation of the 
benefits of, and the need for, proper evaluation must be developed before evaluation 
can be fully accepted and implemented on a regular basis. The WHO vision of the 
value of treatment evaluation is founded on the belief that planning and delivering 
specific treatments should be based on a careful analysis of needs, competing 
demands, knowledge of the relative cost-effectiveness of alternative means of deliv-
ering services and the explicit recognition of the scarcity of resources and the need 
for maximum efficiency in the way they are used. 
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CHAPTER 9 
THE POLICY-MAKER'S PERSPECTIVE 
Elfriede Koller 
In Germany, the number of treatment facilities for drug abusers has increased in the 
last few years, as treatment is generally considered the most effective way of reduc-
ing drug-related problems. Having been told that 'no two drug users are the same', 
the diversification of treatment received the full support of national decision-makers. 
Treatments targeted at drug-dependent women, families and ethnic minorities were 
all encouraged, as were short-term, long-term, in- and outpatient treatments. Low-
threshold units were also created and maintenance programmes came to be seen 
as crucial. 
However, despite the vast sums invested in the diversification of treatment, most of 
the decisions to fund such treatment modalities were not based on scientific evi-
dence and did not lead to results any better than the 'rule of thirds': one-third of 
clients achieve abstinence; one-third improve, but are not abstinent; and one-third 
make no progress. 
Since their establishment, some of the new approaches have been evaluated, but 
again, in many cases, this assessment has been found to have little scientific basis 
- all too often, the new project was found to be 'essential' only as a means of 
ensuring future funding. As far as this author is aware, no published evaluation 
research has found that the treatment being assessed is of no benefit at all to its 
clients. 
Fundamentally, and until very recently, no-one has even been able to compare one 
treatment with another to see what is 'successful', nor has there been any compara-
tive evaluation of short-term versus long-term treatment. Governments therefore 
finance this broad range of diverse treatment approaches in order to offer different 
choices to different people - even though the success of this variety of options 
remains unproven. 
Policy- and decision-makers clearly suffer from this lack of accurate evidence, and 
end up being buffeted by the forces of 'opinion-makers', rather than being guided 
by scientific research. The problem, of course, is that national drug policy depends 
on a wide variety of interests and influences, such as public opinion and media 
pressure to come up with innovative and effective ways to tackle the threat of drug 
abuse. 
The interests of treatment centres to survive, of clients to have the most individual 
and accessible route into treatment, and of insurance companies that pay for such 
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treatment and have their own philosophy of standards, costs and outcomes must also 
be weighed up. While these pragmatic aspects are rarely considered by researchers 
undertaking treatment evaluation, for better or worse, they do play a central role for 
decision-makers. 
The need for robust treatment evaluation 
Drug treatment in Germany is generally considered to be of high quality. Evaluation 
is of the utmost importance in this system, but the questions asked are no longer 
simply whether an effect occurs or not or whether a programme is 'good' or 'success-
ful'. Instead, evaluation today is linked to supporting objective-oriented develop-
ment. This is because there has been a fundamental change in the way treatment is 
perceived in Germany. 
National care systems are no longer thought of institutionally, but in terms of the 
functions they should fulfil and the client needs they are expected to satisfy. This 
new perspective changes the way in which the individual parties providing help in 
the health-care system co-operate with one another: co-operation is changing from 
an essentially static form to a dynamic, goal-oriented one. As a result, evaluation 
now has to focus on the function of assistance, not on the institution providing that 
help. 
Meanwhile, 'productivity', 'quality', 'efficacy' and 'outcome' are all common 
terms within drug-treatment centres. But these terms alone do not make a treat-
ment. In order to provide the right help to the right people, the demand for success-
ful co-ordination and co-operation needs to be placed within the context of local 
monitoring and steering. In other words, evaluation needs to be seen as more 
significant than simply a means of representing and assessing treatment conditions 
and performance. 
Within this model, evaluation has the task of finding the most effective form of care 
for a particular client at a particular time. Even now, such a requirement is not 
deemed to be an important factor in scientific evaluation - but it wil l clearly become 
a vital issue in the future. 
If evaluation cannot answer this most basic of questions - what treatment is best 
suited to which client? - the drug-care system has no future at all. Instead, family 
doctors, social services, psychiatric institutions and rehabilitation clinics could well 
take over the care of drug users. 
The need for inter-sectoral co-operation and co-ordination 
In Germany, the distinction between care for those addicted to legal drugs and those 
addicted to illegal drugs is becoming blurred. These two fields of care developed in 
almost complete isolation, but the lines of separation are now being increasingly 
questioned. 
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With the more integrative perspective described above, policy- and decision-
makers are realising that few drug misusers actually follow the 'classic career'. As 
such, addicts are no longer considered as a population that should be cordoned off 
from the general public. The effectiveness of creating such 'enclaves' is disputed, 
and health and social services that cater to the general population are now being 
urged to open their doors and meet the requirements of drug addicts. The expectation 
is that intra- and, above all, /nfer-sectoral co-operation wil l improve, leading to a 
more effective provision of help to those addicted. 
Given this situation, evaluation research should now examine the question of inter-
sectoral co-operation. This term refers to concept-controlled, objective-oriented co-
ordination between public bodies, private institutions, networks and helping services. 
The care system 
The current care system for drug addicts in Germany is made up of the following 
three sectors. 
• Sector I is specifically for drug addicts and abusers, and provides special advice 
centres and clinics. As stated at the beginning of this chapter, within the last decade, 
this sector has expanded and 'traditional' drug-based treatments are now enhanced 
by low-threshold services, street work, harm-reduction and damage-control 
techniques. 
• Sector II provides psycho-social and psychiatric aid within public, social and 
health-care institutions. This sector deals with 'difficult' cases, clients not moti-
vated to change and chronic addicts. 
• Sector III is the basic medical system, encompassing physicians, family doctors 
and general hospitals. Most drug addicts are treated - initially at least - within 
this sector, but in general, the medical sector has little competence in the speci-
fic area of addiction, as all the public money for drug care tends to go to Sector I. 
This fragmentation and lack of co-ordination means that the system as a whole leans 
towards institution-related thought and action. The resultant tendency is to select 
clients according to the criteria of the particular institution. This creates a situation 
in which Sector I cannot adequately satisfy the requirements of chronic addicts. The 
irony is that the clients requiring the most help - who wil l have complex social and 
health problems which cannot be tackled effectively by a psychiatrist - as a rule 
receive the least assistance. 
The needs of the policy-maker 
All the above reinforces the need for better inter-sectoral co-operation and co-
ordination, issues which should concern any future evaluation. This requirement 
also implies that evaluation research must focus both on treatment systems as a 
whole and on the individual case. 
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A 'community system' consists of various agencies, care and treatment settings, 
providing both specialist and generic services. Evaluation should examine the impact 
of these agencies and services on individual clients and monitor their progress across 
a range of objectives. As far as this author is aware, systematic research is not carried 
out at these two apparently opposite ends of the spectrum - the treatment system and 
the individual. 
Decision-makers want to learn what benefits clients can receive from a given drug-
care system, and what type of client has what specific need. In short, they want a 
client-oriented picture, notan institution-oriented one. At this policy level, evaluating 
the 'success' of a single service is therefore not the primary objective. On the other 
hand, regional treatment systems can only be planned or restructured if community 
systems are evaluated. 
Recommendations for future action 
This chapter has sought to show that evaluation needs to become a tool to promote 
structures and systems according to specific goals. It has also stressed the urgent 
need to evaluate inter-sectoral co-operation, a task that would require new con-
cepts and definitions. 
New concepts 
To start with, the status quo would need to be analysed and the following questions 
addressed: 
• How many people require specific interventions for certain addiction-related 
problems? 
• What institutions with what resources offer what type of help for what type of 
problem? 
• Which clients with what problems wil l be reached by those offers of help? 
Such an analysis of a given situation wil l provide an initial picture of the 'helping 
network', including the co-operative relationships within and between the different 
care sectors. The evaluation also has to distinguish between the two types of co-
operation: institution-related co-operation; and client-related co-operation. 
An analysis at this level wil l uncover the strengths and weaknesses as well as the 
advantages and disadvantages of existing collaboration. The following questions 
should be posed: 
• What overlaps and deficiencies are there in the provision of individual care? 
• Have personal responsibilities been made clear to the clients and if so how has 
this been done? 
• Has information exchange and co-operation been formal or informal? 
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• At what levels does co-operation take place and in what form? 
• Are offers of treatment agreed and measures co-ordinated, and if so how is this 
done? 
• Are joint activities planned and carried out? 
• Are resources used jointly? 
• Do institutional links exist? 
• What weak points of co-operation and co-ordination can be identified? 
Client-related co-operation 
Client-related co-operation should also be investigated, and this investigation should 
be carried out in a standardised and qualitative manner. The following parameters 
should be recorded: 
the goal and type of aid; 
the continuity of the provision of help in terms of personnel and concept; 
the participating workers; 
the type of client information shared or exchanged with other professionals; 
the frequency and form of such information exchanges; 
the scale and nature of co-ordination of the assistance provided to the client; and 
client participation. 
This investigation should assist in developing recommendations for improving the 
effectiveness and efficacy of an observed network or care system. 
Da fa collection 
Within the framework of inter-sectoral co-operation, data must be collected in a 
manner that allows comparisons to be made and the 'treatment trail' to be followed. 
For conclusions to be drawn about the relationship between the care system and the 
use that clients make of it, while respecting client confidentiality, the clients need to 
be identifiable, at least in coded form. 
Professional views 
Finally, drug workers themselves can provide useful information on certain issues 
which improve or hinder their work. A worker questionnaire should therefore be pre-
pared to collect information on professional and 'ideological' views, as well as on 
possible areas of competition for clients and resources. This analysis should 
concentrate on areas where either obvious differences or common ground can be 
perceived. 
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The role of the EMCDDA 
With the European Monitoring Centre for Drugs and Drug Addiction supporting the 
above procedures, there would at last be more - and better - evaluation which could 
reinforce and intensify the monitoring of the treatment process according to its over-
all goals. The ultimate goal must be that such a targeted evaluation could uncover 
hitherto unseen relationships within an overall treatment system, leading to a policy 
or strategy which could make the entire experience fruitful for both the care system 
and its clients. 
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COST A - 6 ' S C O N T R I B U T I O N TO 
T R E A T M E N T EVALUATION 
Ambros Uchtenhagen 
Since the early 1990s, European Co-operation and Co-ordination in the Field of 
Scientific and Technical Research among European Union and European Free Trade 
Association Countries (COST) has developed research programmes in ten areas of 
the social sciences. Drug abuse is one of these ten areas. 
COST A-6, Evaluation of Action against Drug Abuse in Europe, was established on 
the initiative of a group with differing interests. This explains its diverse working pro-
gramme that focuses on the evaluation not only of drug policy, but also of 
primary prevention, treatment, rehabilitation and action against drug-related delin-
quency. 
The programme ran from December 1992 to December 1997 with the collaboration 
of 15 European countries and invited observers from the Commission of the 
European Union, the United Nations International Drug Control Programme 
(UNDCP), the World Health Organisation (WHO) European office and the 
Pompidou Group of the Council of Europe. It also established links with a number 
of European professional associations - the European Federation of Therapeutic 
Communities, ITACA and the Federation of European Professionals Working in the 
Field of Drug Abuse (ERIT) - and research groups - such as the Social Science 
Research Group on Drug Dependence, the International Study on Drug Treatment 
Systems and the European Association on Substance Abuse Research. 
The main objectives of COST-A6 were to: 
• establish networks of researchers at national and international level; 
• collect and analyse relevant research material; 
• develop protocols and instruments for evaluation research; and 
• stimulate international multi-site evaluation research. 
Protocols and instruments 
A working group was also set up to develop research protocols and instruments. 
Chaired by Anna Kokkevi and Ambros Uchtenhagen, this group focused primarily on 
developing a client information system, selecting from the available instruments the 
Addiction Severity Index (ASI) and adapting it to European conditions. A manual for 
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using the European Addiction Severity Index (EuropASI) was published in 1995 
(Blanken et al., 1995). Translations are now available in Dutch, English, Finnish, 
French, German, Greek, Italian, Russian and Spanish, while versions of EuropASI in 
other languages are currently being prepared. 
The validity of EuropASI was initially assessed within the framework of a co-
morbidity study co-ordinated by Anna Kokkevi, and guidelines for validation studies 
in various other countries are also being developed. Training courses for EuropASI 
have been held in Belgium, Germany, Greece, Italy and the Netherlands. A final 
workshop was run in collaboration with the European Addiction Training Institute in 
November 1997. 
The second aim of this working group was to identify a similar instrument for gath-
ering information on drug-treatment services. As none of the existing instruments 
were deemed to satisfy every need, the group developed its own Treatment Unit 
Form (TUF), a preliminary version of which is now being piloted by the EMCDDA. 
The results of this study wil l inform the group's future work. 
National funding has also helped in developing systems to monitor treatment 
services. In Stockholm, V. Segraeus has developed another model for gathering 
information on drug treatment, while in Zurich, S. Schaaf has carried out a 
comprehensive review of all treatment-information models and instruments as the 
basis for conceptualising a modular instrument to describe substance-abuse 
treatment (MIDES). 
Treatment evaluation 
Alongside the working group developing research protocols and instruments sat 
another group - chaired by M. Coletti - to examine the evaluation of drug treatment. 
This group's objectives were to: 
• review relevant European evaluation studies; 
• review the methodology and instruments used in such studies; and 
• build a European network of scientists and professionals engaged in evaluation 
research, so that information can be exchanged, workshops run and guidelines 
on treatment evaluation prepared. 
The group commissioned country reports from Belgium, France, Germany, Greece, 
Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the UK 
which summarised the results, focus and methodology of evaluation studies already 
carried out in these countries. The reports revealed an extremely diverse picture of 
treatment evaluation, reflecting not only different treatment systems, but also differ-
ent research priorities. Whereas fol low-up studies of individual treatment 
programmes were the norm in most countries, others - most notably Germany, 
Norway, Switzerland and the UK - had made considerable efforts to develop sys-
tematic client-documentation and treatment-evaluation systems on a national basis. 
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Germany has two national documentation systems: EB1S for out-patient treatment 
(set up in 1980); and SEDOS for in-patient treatment (set up in 1994). In Switzerland, 
there are four such systems - SAMBAD for out-patients (1996), SAKRAM for in-
patient alcoholics (1992), FOS for in-patient drug misusers (1996) and PROVE for 
prescribing narcotics (1994). SAMBAD, FOS and PROVE are largely compatible with 
each other and with EuropASI. The UK currently has one national documentation 
system, the Maudsley Addiction Profile (MAP), for in- and out-patients (1995, see 
Chapter 8 above) and a national system is currently under construction in Norway. 
Based on an analysis of the country reports, the working group produced a paper 
which reviewed the various national documentation systems as a basis for compar-
ative evaluation. 
The group has also commissioned a number of studies on specific aspects of treatment-
evaluation methodology. For researchers, the focus has been on outcome evaluation; 
for practitioners, on process evaluation; and for administrators, on cost-benefit 
analysis. Adequate instruments for process evaluation and cost-benefit analysis have 
yet to be identified and developed. 
Based on the group's work on methodological issues - as well as a number of other 
recent studies (Graham ef al., 1994; WHO, 1991; US General Accounting Office, 
1990)-guidelines wil l be developed for treatment evaluation which can be used not 
only for self-evaluation, but also for comparative evaluation of different treatments. 
Training courses wil l also be organised for researchers, professionals and adminis-
trators providing an introduction to the methodology of self-evaluation, comparative 
evaluation and the implementation of evaluation results. 
International research projects 
A number of national research projects and four multi-site international studies have 
been initiated on the basis of material prepared by COST A-6. These four are: 
• The co-morbidity study, which tested the validity of EuropASI through the dual 
diagnosis of out-patients and those in residential treatment. This study was co-
ordinated by the Athens University Mental Health Research Institute, and 
involved Germany, Greece, Italy and the Netherlands. 
• The University of Maastricht has co-ordinated a study aimed at improving psy-
chiatric treatment by preventing relapse in residential programmes for newly 
dependent drug users. The participating countries were Belgium, France, 
Germany, Greece, the Netherlands, Italy, Spain and the United Kingdom. 
• A Delphi study, co-ordinated by the Ludwig Boltzmann Institut für 
Suchtforschung in Vienna, aimed at achieving a consensus on the format and 
content of evaluation in primary prevention. Participants included Austria, 
Germany, Italy, the Netherlands, Poland, Portugal, Spain and Switzerland. 
• At the time of writing, multinational research on cross-border drug-related delin-
quency, drug tourism and street-level policing was also in preparation. 
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An extensive report on the Delphi study and a report from the working group on the 
evaluation of policies are both now available (Springer and Uhi, 1998; Waal, 1998), 
although the other project reports are still in preparation. 
Recent European drug research and future research needs 
On behalf of the EMCDDA, the COST A-6 chairpersons have prepared an overview 
of recent international studies in the fields of epidemiology, drug policy, drug-related 
delinquency and the evaluation of primary prevention, treatment/rehabilitation and 
harm-minimisation approaches. They also made recommendations for future 
research in these fields. The recommendations relevant to treatment evaluation were 
as follows: 
• methods should be defined to enable treatment needs relevant to the develop-
ment of treatment services to be identified; 
• treatment networks in a given territory should be evaluated; 
• comparative assessments of cost-effectiveness in treatment should be undertaken; 
• the effects and limitations of non-professional interventions should be evaluated; 
• treatment accessibility for high-risk groups (deprived youth, refugees, prison 
inmates, etc.) should be evaluated; 
• more research is needed into the reasons for post-treatment relapse; and 
• quality standards and quality assurance in substance-abuse treatment need to be 
developed. 
Collaboration with the EMCDDA 
Major steps have already been taken by the European Monitoring Centre for Drugs 
and Drug Addiction to continue the work initiated by COST A-6. The monograph 
Evaluating Drug Prevention in the European Union (EMCDDA, 1998a) and the 
Guidelines for the Evaluation of Drug Prevention (EMCDDA 1998b) have also 
helped determine how the theoretical work carried out by COST A-6 can be further 
developed and implemented through the REITOX system. 
To this end, a joint workshop was held in Zurich in December 1997, which signified 
a symbolic 'hand-over' of the work on treatment evaluation from COST A-6 to the 
EMCDDA. 
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WORLD HEALTH ORGANISATION 
PROGRAMME ON SUBSTANCE ABUSE 
Maristela Monteiro 
From the public-health perspective, it is becoming increasingly evident that substance 
use plays a major role in morbidity and mortality on a world-wide scale. Despite 
efforts at controlling the supply of illegal substances and an increase in initiatives for 
primary prevention, large numbers of individuals are developing harmful or dependent 
patterns of substance use, leading to disorders requiring treatment. 
As defined by the World Health Organisation (WHO), health is 'not only the absence 
of infirmity, but a state of complete physical, mental and social well-being'. The term 
'treatment' should, therefore, be used to define the process that begins when psy-
choactive substance users come into contact with a health provider or service, and 
continues through a systematic succession of specific interventions until the highest 
attainable level of health and well-being is reached. Treatment thus includes compre-
hensive approaches to detection, assistance, health care and the social integration of 
those people that present problems as a result of psychoactive substance use. 
Treatment evaluation 
While recognising the great difficulty of conducting properly controlled and valid 
research in the area of treatment evaluation, the questions of cost and effective-
ness can still be investigated and prioritised. This approach would help to ensure 
the most effective use of available human and financial resources. 
To rationalise the allocation of resources for teatment based on evaluation, it is first 
necessary to educate policy- and decision-makers, as well as programme-managers, 
in the need for such assessment. An appreciation of the benefits of, and the need for, 
proper evaluation must be developed before this procedure can be fully accepted 
and implemented on a regular basis. 
Substance-use services can be evaluated on many levels. These levels include the 
treatment components, services, programmes and systems. At its simplest, evaluation 
may focus on individual treatment activities or components, such as one-to-one 
counselling or pharmacotherapy. At the service level, assessment focuses on the 
individual or on the combined effects of interrelated treatment activities. At the pro-
gramme level, evaluation focuses on single or multiple treatment services provided 
by a single administrative entity. Finally at the systems level, the evaluation focuses 
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on the full complement of programmes available either in a defined community, in 
larger geographic regions or at national level. This chapter looks at each of these 
levels of evaluation. 
Evaluation goals 
Treatment evaluation should be seen above all in the context of a society that 
endeavours to reduce substance-use problems by providing accessible and afford-
able treatment services and strives unremittingly to improve their quality and 
effectiveness, within the constraints of available resources. 
Two broad goals have been developed to help guide this vision. The first concerns 
the overall allocation of resources for treatment services. The second concerns the 
distribution of these resources across the continuum of services. 
• Goal 1: the allocation of resources to plan, deliver and evaluate psychoactive-
substance-use services should be appropriate to the size of the burden that 
such substance use is placing on that society and the availability of resources to 
reduce that burden. 
• Goal 2: specific types of substance-use service should be planned and delivered 
on the basis of a careful analysis of needs, competing demands, knowledge of the 
relative cost-effectiveness of alternative forms of service delivery and the explicit 
recognition of the scarcity of resources and the need for maximum efficiency in 
their use. 
The World Health Organisation 
To achieve these two broad objectives, the aims of the World Health Organisation's 
project are to: 
• increase awareness of the role of evaluation in planning and delivering 
substance-use services; 
• increase knowledge of different types of evaluation, their purposes and limita-
tions; 
• increase confidence and skills in planning and undertaking evaluation activities, 
especially outcome and economic evaluations; and 
• increase the use of evaluation results to improve decisions about programme 
enhancement and resource allocation. 
Why undertake evaluations? 
On a general level, evaluation is concerned with obtaining feedback about the oper-
ation, effectiveness and efficiency of a treatment activity, service, programme or 
system. This feedback can be put to several different uses, and the reasons for a 
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particular evaluation must therefore be made explicit from the outset since this will 
influence all aspects of its planning, design and conduct. 
Most of the reasons for undertaking an evaluation fall into two categories: 
• First, many evaluations are undertaken from the perspective of accountability. 
Such studies often set out to judge whether the treatment programme is actually 
delivering what it has promised, either in terms of the services provided or the 
outcomes achieved. Accountability evaluations place considerable emphasis on 
assessing the efficacy or cost-effectiveness of the programme by using rigorous 
scientific methodologies and are usually conducted by external evaluators in 
order to bring objectivity to the evaluation process. 
• Second, many evaluations are undertaken from a quality-improvement perspective. 
These have the explicit objective of enhancing the service rather than judging its 
overall worth or accountability. Such studies may examine a wide range of 
issues related to the cost, delivery and effectiveness of the service. 
• Evaluations based on quality improvement are often undertaken with more lim-
ited evaluation resources than scientific evaluations, and are usually conducted 
internally. Increasingly, these internal evaluations take place in a participatory 
fashion involving, for example, key stakeholders such as managers, treatment 
staff, community partners and the service's clients themselves. 
As well as clarifying the theory that ties together service activities and objectives, 
evaluation is also undertaken to determine the philosophy and principles underlying 
the service. Clarification of these principles makes selecting appropriate outcome 
measures easier. For example, evaluating a service based on harm reduction could 
focus on broader outcomes than a service based on abstinence. 
Discussing people's expectations of the evaluation and their value system, and con-
ducting a systematic review of the programme's logic model greatly facilitates the 
identification of the key questions and issues that the evaluation should address. 
These questions and issues should then be prioritised and the details of the evalu-
ation planned. The evaluation assessment culminates with a clear statement of: 
• the components of the service to be evaluated; 
• the questions to be addressed; and 
• the specific data-collection strategies, measures and analyses to be employed. 
It also includes a work plan for the evaluation itself. 
Needs assessment 
There is no universally agreed definition of 'need'. For example, some countries 
whose national policies do not tolerate any substance use may prevent methadone-
maintenance programmes from being implemented. In states where alcohol use is 
prohibited, controlled drinking is not an achievable goal. Despite the content of 
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national policies, the philosophies of some services may also determine the treat-
ment goals, regardless of the needs of the population to be treated. 
Needs assessment usually involves two distinct phases: 
• need identification; and 
• need prioritisation. 
A variety of approaches and data-collection strategies may be used to identify need. 
Some methods - such as population surveys, focus groups or community fora -
collect information directly from community members, while other approaches -
such as key informant surveys or the Delphi technique - rely on input from 
professionals in the field who are thought to be particularly knowledgeable about 
the needs to be addressed. 
Other approaches use statistical indicators to assess the nature and extent of substance-
use problems in the community (such as drug-related crime, liver cirrhosis mortality 
rates, traffic accidents and family breakdown) as direct or indirect measures of com-
munity need. Each of these methods has its strengths and limitations and thus a 
convergent approach using a combination of these procedures is recommended. 
The following questions tend to be asked in a needs assessment: 
• What is the prevalence and incidence of substance-use disorders in the community? 
• What type of treatment intervention should the service provide? 
• What are the main gaps in the community treatment system? 
• What is the projected demand for treatment in the community? 
For needs assessments undertaken at community level, it is common practice to 
conceptualise an ideal continuum of services and then to use this as a template with 
which to assess the availability and accessibility of local or regional services. 
Estimates of the anticipated demand and the resource requirements for a specific 
treatment service may also be derived. 
It is, however, often difficult to prioritise identified needs because of the political 
nature of the decision-making process and the lack of clear protocols that reduce 
bias. If the task is to prioritise which geographic area has the highest need, it may be 
possible to develop composite indices of various need indicators and then use the 
ranking of this index to prioritise the various areas under consideration. If, on the 
other hand, the task is to select the highest priority among a range of service options, 
then a structured decision-making approach such as a Multi-Attribute Utility 
Analysis could be used to achieve group consensus and reduce bias. 
Costing frameworks 
The broad aim of costing studies is to trace the resources used under different 
circumstances. There are three main ways in which costs could be addressed: 
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• by estimating the social cost to the community of substance-use problems; 
• by undertaking cost-minimisation studies, which compare the costs of alternative 
treatments where outcomes are assumed to be equivalent; and 
• by using treatment-resource tracing, which produces a detailed analysis of the 
different costs involved in delivering a service with an emphasis on how costs 
may change in relation to activity levels within the service. 
Social costs 
Social-cost studies trace the impact of a particular substance within a specific loca-
tion in an allotted time period. Information on the burden that a particular substance 
places on a society helps to guide policy action. The disadvantage of such studies is 
that they do not in themselves evaluate alternative policies which may reduce this 
burden. 
Cost-minimisation studies 
In a cost-minimisation study, the resources needed to deliver different treatments are 
calculated and compared. If outcomes are found to be equivalent, it may suggest 
that the treatment that required the least resources should be considered further. In 
most cost-minimisation studies, only the direct resources concerned in delivering 
care are compared. However, since people with substance-use problems use more 
health and welfare services than people without such problems, the expected 
resource needs across the whole range of health and social welfare services should 
be considered. 
These studies may be used as a preliminary check on the feasibility of treatment 
options prior to a more detailed outcome or economic evaluation. If there is firm 
evidence to suggest that there would be no difference in outcomes across the many 
domains considered, a cost-minimisation comparison could be seen as a form of 
economic evaluation. 
Treatment-resource tracing 
These studies are designed to examine the costs of the resources required to deliver 
specific units of service (such as counselling sessions). The information from such 
research can be used by providers to set their charges and monitor whether 
resources are being used as planned. For such evaluations, it is important to distin-
guish between fixed costs and semi-fixed costs. 
Outcome evaluation 
The two tasks of treatment-outcome research are: 
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• to measure change associated with treatment; and 
• to infer causality. 
A number of evaluation designs allow these two tasks to be achieved to varying 
degrees. 
Design models 
As discussed in earlier chapters, the most widely praised design in terms of measuring 
change and inferring causality is the randomised control trial, wherein patients are 
randomly assigned to receive one of two or more treatment options. From the 
scientific point of view, such trials are considered the 'gold standard' in evaluating 
treatment effects, because the design allows for the inference of causality, and 
changes may be more easily attributed to the treatment examined rather than to 
other extraneous factors. 
Another design model, which is still relatively robust in its ability to allow causal 
inference, is the 'quasi-experimental' approach, wherein patients are not randomly 
assigned to treatment. Rather, two groups of patients which have received two 
different treatments are compared. In this design, the ability to make strong infer-
ences of causality is improved if patients in the two treatments are matched or if 
pre-treatment differences are adjusted statistically. If such a matching or statistical 
adjustment does not take place, it is possible that any variations which favoured 
one treatment over the other were due to factors that presented prior to the start 
of treatment. 
Nonetheless, even a two-group comparison without matching or adjustment is more 
useful in determining the relative effectiveness of treatment than a single-group 
design. These studies simply analyse the progress of a group of patients over time and 
do not allow any inferences to be made about relative effectiveness. Patients are 
monitored in terms of changes from pre- to post-treatment, and these changes are 
directly attributed to the treatment provided. The strength of this inference, however, 
is quite weak because patients may improve simply because of the passage of time or 
as a result of other unrelated factors. 
The weakest method of determining causation is the single-group study where 
patients are assessed only at the end of treatment. Although the clinician may have 
faith that the patients have improved, with no measure of pre-treatment problems it 
is impossible to draw conclusions about the extent of change and its relationship to 
the provision of treatment. 
Whatever evaluation design is selected, the issue remains of which outcomes wil l 
be measured and how. Measures should be reliable, scientifically valid and appro-
priate to the interventions' objectives. This means that the measures must be sen-
sitive to behavioural change over time, and able to assess the patient's well-being 
accurately. 
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A number of domains are typically included when examining outcome: 
• substance-use frequency and pattern; 
• psychological functioning; 
• physical health (including HIV status); 
• social adjustment; 
• family functioning; 
• employment; and 
• criminal activity. 
It is not, however, always necessary to measure all these factors when evaluating a 
treatment approach. 
Economic evaluation 
Economic evaluations can be used to answer different questions. For example, 
funders, policy-makers or even the general public may require an answer to the 
question 'is treatment worthwhile and does it result in more benefits than costs?' 
Both providers and funders of services may be interested in the answer to questions 
such as 'which of the treatment options or combinations provides the best value from 
the budget available?' 
A more generally relevant question for publicly funded health and welfare systems 
concerns the choice of allocating resources to different client groups or types of 
provider agencies. For example, the question may be asked of how to distribute 
available resources between treatment services and other types of health-care services. 
Economic evaluations require the identification of all costs and benefits for the alter-
natives under consideration. As already outlined in Chapter 5 above, costs can be 
direct or indirect, while benefits involve positive changes in the quality of life for the 
individual, his or her family and society as a whole. 
Conclusions 
In conclusion, the following recommendations can be made: 
• that governments and policy-makers encourage and support the standardised 
evaluation of treatment approaches to substance-use disorders; 
• that governments use results from evaluations of cost-effectiveness when planning 
national treatment services in order to allocate resources more efficiently; 
• that governments use concepts of equity in providing accessibility to treatment; 
• that governments in all W H O Member States plan national treatment systems 
taking into consideration local evaluations of effectiveness and the economic 
efficiency of different treatment approaches; 
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that the WHO Programme on Substance Abuse co-ordinates the production and 
testing of guidelines on treatment evaluation to be used by programme-managers 
and administrators; and 
that programme-managers and administrators plan, develop and implement 
activities, programmes, services and systems to evaluate treatment, and use the 
information gathered from them to improve the cost-effectiveness of treatment 
provision. 
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W O R K S H O P S U M M A R Y 
Anna Kokkevi 
The need for treatment evaluation 
Given both the growth in drug-related problems and the limited resources that can 
be dedicated to reducing them in a period of economic constraint, the need prop-
erly to manage the cost-effectiveness of treatment and to ensure the highest quality 
and best outcomes for the lowest possible cost are indisputable priorities. 
In Europe, drug-treatment evaluation research has been mainly limited to small-scale 
clinical studies. The UK's National Treatment Outcome Research Study (NTORS) is 
one of the exceptions to this rule, being probably the first large-scale, nationwide 
attempt to evaluate drug treatments in Europe. 
A multi-centre European study, carried out in five countries and entitled 
Psychosocial Problems and Psychiatric Co-morbidity among Drug and Alcohol 
Dependent Persons applying for Treatment, also includes a number of evaluation 
parameters and standardised assessment instruments. However, it must again be 
emphasised that such studies are rare and so, to date, much of the discussion about 
measuring treatment effectiveness has centred on academic debate. 
The effectiveness of drug treatment 
Three positions in this debate were presented during the workshop. 
• The nihilistic position questions whether the right to treatment and care, based 
on ethical standards of medicine, is a sufficient basis for allocating scarce 
resources. If - as has been claimed by some - treating problematic drug users 
produces poor results at best, then not only treatment development, but also the 
allocation of funds need to be reconsidered. If, on the other hand, treatment is 
seen to mitigate drug-related problems, evidence must be provided for this based 
on valid and reliable data. 
In support of the argument for evidence-based treatment, Mats Fridell sought to 
clarify the traditional misconception of the high 'spontaneous remission' of 
addiction. This concept could lead to the false and even dangerous belief that 
treatment is of limited value, as the individuals undergoing it would have 
recovered anyway. Spontaneous remission at rates of 50%, as reported by some 
studies, would seem to indicate that treatment is in fact not worthwhile. In 
such a case it could be argued that spontaneous remission is less costly than 
treatment. 
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However, well-documented studies reviewed by Fridell show that spontaneous 
remission is actually in the range of 10-15%. This illustrates the methodologi-
cal pitfalls that can lead to false claims about the effectiveness or otherwise of 
treatment. In his presentation, Fridell stressed the need to apply appropriate 
methodology to satisfy valid treatment-outcome evaluation. 
• The utopian position faces many of the same problems as the previous one. 
Vincent Hendriks referred to studies that reported treatment effectiveness at 
levels of 80% and above. He argued that such studies are in reality boosting their 
results by applying evaluation approaches designed to cope with pressure from 
funding organisations and to satisfy expectations, rather than ensuring evaluation 
validity. 
• The realistic position was posed by both Fridell and Hendriks. The current posi-
tion - according to Hendriks' literature review - seems to follow the 'rule of 
thirds': one-third of clients achieve abstinence; one-third improve, but are not 
abstinent; and one-third make no progress. 
A recently completed Swedish study reported by Fridell found that at five-year 
follow-up, 40% of heavy drug abusers who had undergone detoxification or short-
term rehabilitation had been abstinent for two years. There was also an overall 
decrease in all forms of drug consumption and a significant reduction in criminal 
activity. Fridell also cited a recent UK overview which concluded that success rates 
for the treatment of substance disorders are as high or higher than those for many 
other chronic ailments, and that any critical appraisal of the effects of drug treat-
ment must include comparisons with other types of treatment for other medical 
conditions. 
Evi Hatziandreou also pointed out that the (albeit limited) number of available 
studies suggest that the benefits of treatment seem to be at least as great as its 
costs. 
Concepts used in evaluation research 
Mats Fridell clarified and distinguished the concepts most frequently applied in eval-
uation research as follows: 
• productivity the relationship between achievements and resources; 
• effect the relative difference between two treatment methods or a 
specific treatment method and control groups that receive 
an alternative treatment or placebo; 
• effectiveness the relationship between effects and resources; 
• efficacy the measurement of the relative scale of an effect in a 
treatment meta-analysis; 
• treatment outcome a concept deemed to be more appropriate and precise than 
either 'effect' or 'efficacy' when evaluating residential treat-
ment. 
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Evi Hatziandreou further clarified the basic concepts used in economic evaluation 
research: 
• cost-benefit the ratio between the costs and benefits - both measured 
in monetary terms - that arise from a particular treatment 
intervention; 
• cost-effectiveness the ratio between the costs and benefits that arise from a 
particular intervention, where benefits are calculated in 
'health' and 'social' rather than in monetary terms; 
• direct costs the measurement of the value of resources consumed 
(both health- and non-health-related); 
• indirect costs the measurement of the value of lost productivity; 
• intangible costs the measurement of costs relating to the isolation, stress, 
pain and suffering of those afflicted by substance abuse. 
Meeting the needs of the practitioner 
Heinrich Küfner pointed out that clinicians and practitioners are more interested in 
the evaluation of single treatment components than the overall evaluation of treat-
ment. It is rare for evaluations to provide an indication as to 'what works', although 
estimates of cost and evidence of the benefits of individualised approaches can be 
made. 
Küfner also stated that evaluation results have a limited influence on the treatment 
system. He explained this situation both in terms of the problems and the limitations 
inherent in evaluation research and of the shortcomings of some clinicians. 
In reality, social trends have more influence on treatment directions than do the 
results of evaluation studies. But, despite the neglect or under-use of evaluation 
results and the problems encountered, Küfner felt that there is no alternative to eval-
uation. 
He further underlined the need for a close relationship between researcher and 
clinician. This collaboration can lead to the identification of clinically significant 
evaluation criteria. 
Meeting the needs of the policy-maker 
Elfriede Koller presented the point of view of the policy-maker regarding what is 
expected from treatment evaluation. Treatment effectiveness needs to be proved by 
means other than 'face validity' criteria, and policy-makers need to know how input 
(money) and outcome (socially integrated clients) are balanced. 
Policy-makers also require information on the comparative effectiveness of different 
treatment approaches. This will help in planning treatment more effectively, as well 
as in assessing the care system as an integrated entity, rather than focusing on a 
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specific institution or programme. Ultimately, policy-makers want to be able to 
identify gaps in inter-sectoral co-operation and help improve this co-operation to 
ensure better co-ordination. 
This last point was also approached in economic terms by Evi Hatziandreou. She 
introduced the notion of opportunity cost (the value of the best alternative which is 
foregone) and further clarified that the real cost of any programme cannot be judged 
in budgetary terms, but rather by the health and social outcomes that have not been 
achieved elsewhere. The objective for a society should be to maximise the total 
benefits to its members. 
Methodological designs for treatment evaluation 
A central issue in designing evaluation research is that of the representativeness of 
client samples. Representativeness is a prerequisite for the generalisation of findings. 
Issues relating to methodological designs were discussed in the contributions from 
Vincent Hendriks, Mats Fridell and Fabio Mariani. 
Although the randomised control design is the design of choice for yielding valid 
results on treatment outcome, there are practical and ethical constraints within the 
drug-treatment sector on randomising clients into treatment and non-treatment con-
ditions. 
Naturalistic studies, comparing pre- and post-treatment, are the most typical evalu-
ation studies carried out. But a number of confounding variables can be expected 
to influence the treatment outcome in non-randomised designs, thus limiting the 
validity of conclusions on treatment effect. 
Problems related both to randomisation and to its lack were discussed by Hendriks, 
who concluded that both research designs may seriously threaten the validity of out-
come results in naturalistic settings. He advocated opting for two alternative 
approaches instead: 
• to apply non-randomised designs that provide an opportunity to compensate for 
the loss of 'power' of the randomised approach; or 
• to restrict randomisation to specific components within the treatment pro-
gramme. 
It should also be noted that high drop-out levels might distort the interpretation of 
evaluation results, and they should consequently be considered carefully in designing 
evaluation research. In his presentation, Mariani proposed a method for dealing with 
this problem. 
Evaluation criteria 
Almost all the contributors underlined the need for clearly defined evaluation criteria, 
as well as the need to use standardised instruments for their assessment. To do so 
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requires models and hypotheses describing the main factors contributing to treat­
ment. 
Küfner proposed investing more effort in developing multi­factoral theoretical models 
to account for the process of ending addiction, such as path analysis as applied to 
the development of addiction. These models should be closely related to empirical 
investigations and could be based on systems theory. 
Hendriks proposed the following general regression model 
outcome = constant + client + treatment + process + error 
where treatment outcome is considered as a function of a constant (people can 
change without treatment), a variety of client, treatment and process characteristics 
and an error component. To follow this model, the client, treatment and process vari­
ables need to be assessed appropriately, while complex multivariate regression tech­
niques should be applied to obtain valid results. 
Mats Fridell discussed the issue of single or multiple criteria. Empirical research 
supports the use of multiple criteria, but it should be remembered that the goal should 
not be unrealistic. He used the SWEDATE project (Berglund et al., 1991) as an exam­
ple: by using cumulative criteria, the level of success from a follow­up study dropped 
from 50% when only the criterion of abstinence from drugs was considered, to 10­14% 
when a full set of criteria of a completely rehabilitated individual was taken into 
account instead. 
Evaluation instruments 
Standardised instruments for recording client characteristics have been developed 
for the multidimensional assessment of functioning in various life areas. Most of the 
contributors referred to the Addiction Severity Index (ASI) and to its European adap­
tation (EuropASI). The group discussed the Opiate Treatment Index (ΟΤΙ), a more 
recently developed instrument along the same lines as the ASI, as well as the 
Maudsley Addiction Profile (MAP), which was developed as an assessment instru­
ment for the UK National Treatment Outcome Research Study (NTORS ­ see 
Chapter 8). 
Mats Fridell provided information on standardised instruments that could be used in 
parallel with multidimensional screening instruments like ASI to assess co­morbidity 
in substance abuse. 
Self­rating scales, such as the Symptom Checklist 90 (SCL­90), and personality 
inventories, such as the Minnesota Multiphasic Personality Inventory (MMPI) or the 
Eysenck Personality Inventory (EPI), are widely used, while structured clinical inter­
views, such as the Composite International Diagnostic Interview (CIDI), are also 
available for the assessment of Diagnostic and Statistical Manual (DSM) and 
International Classification of Diseases (ICD) diagnostic classifications. Fridell also 
referred to a seemingly promising scale, the Individual Schedule for Social 
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Integration, that has been developed to assess the social network of drug-using 
patients. 
Hendriks underlined the need to improve the quality of instruments or to widen the 
range of client variables in order to reduce the high level of unexplained outcome 
variance. He supported the view that in addition to treatment-independent 
variables, treatment-dependent client variables (such as motivation for treatment and 
client expectations) should be collected. 
Three areas should be considered for instrument development: 
• the client's preference for a certain type of treatment; 
• the client's addiction model; and 
• the client's stage of change. 
Treatment factors 
As Hendriks pointed out, progress made in quantifying what happens during treat-
ment, both from the client's perspective and that of the treatment, is very limited. 
Treatment still remains very much a 'black box'. Neither treatment as a whole, nor 
the interventions within treatment, are well described and understood. 
The most frequently studied variables are the intermediate variable of time in treat-
ment and the simple description of the type of treatment under investigation. 
Hendriks underlined, however, that increased duration of treatment should not be 
confused with the amount and quality of treatment received. 
Fridell emphasised the importance of measuring the 'therapeutic climate' when eval-
uating organisations and residential treatment. The rationale is that factors like 
'climate' and 'culture' are aggregates of organisational dimensions reflecting the 
selection of patients, the quality and competence of staff members, work satisfac-
tion, conflict levels and organisational structures. The most popular instrument of 
assessment in this domain is the Ward Atmosphere Scale (WAS) which has been 
widely used in Scandinavian studies. 
Fridell recommended involving staff in a continuous, quality-assurance assessment. 
However, evaluation by external researchers wil l be necessary to obtain more reli-
able information on the long-term effectiveness of various treatment modalities. 
Economic evaluation 
The various approaches to economic evaluation in the broader health domain apply 
several common methods: 
• measuring costs only; 
• measuring both costs and health or social consequences; and 
• measuring health-related quality of life. 
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Evi Hatziandreou briefly described these three methods. She further stated that in the 
field of drug misuse, economic evaluation has rarely been applied in a systematic 
and rigorous way. In the past, studies seem to have underestimated the true burden 
on society by failing to consider certain tangible costs that extend to the drug user, 
the environment and to society at large. 
There is still a lack of rigour in cost-benefit and cost-effectiveness analyses. 
Progress is, however, being made, and time-series and modelling techniques have 
been developed to help assess the impact of treatment. Yet, effectiveness still remains 
more difficult to assess than cost and, so far, there is no straightforward evidence as 
to whether drug-treatment programmes are cost-effective. 
Several methodological obstacles still need to be overcome in the field of economic 
evaluation, such as the issue of appropriate experimental design, conceptual 
definitions, selection of objective criteria, controlling confounding variables, 
difficulties in measuring and assigning monetary values and generalising evaluation 
results to untreated populations. 
Evaluation in practice 
The contributions by Umberto Nizzoli and Michael Gossop provided valuable 
insights into how treatment evaluation is implemented in Europe. 
TedEval 
Nizzoli discussed the evolution of a database system and the attitudes of drug 
workers and their managers towards the need for evaluation. With the organisational 
reform of the Italian regions, the need to collect information at regional level led to 
the development of an electronic infrastructure that facilitates the computerisation of 
client information. A 20-item instrument, TedEval, was constructed, describing the 
severity of the client's status and covering six main areas. 
NTORS 
Gossop presented the first results from the NTORS, which aims to provide evidence 
of the effectiveness of national drug-treatment services. NTORS is a large-scale, 
multi-site, prospective study of treatment outcome in a cohort of more than 1,100 
clients who entered drug-misuse treatment services in England during 1995. The 
methodological design of the study is naturalistic - causal inference is achieved by 
comparing pre- and post-treatment outcome measures. 
Pre-existing differences in client characteristics, as well as social and environmental 
differences that might influence outcome across programmes, are precisely mea-
sured so that they can be taken into account in identifying factors associated with 
observed outcomes. 
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The MAP is a set of structured research interviews developed specifically for the 
NTORS project. Items in the MAP include: 
• detailed measures of drug and alcohol use and risk-taking behaviour; 
• physical and psychological health; 
• social functioning (relationships, employment, education and training); and 
• criminal involvement. 
Further measures cover psychological aspects of drug dependence, motivation for 
treatment and coping strategies. Interviews have been designed to be carried out by 
staff at treatment agencies and the information needs of the study have been 
balanced against the burden on staff time of interviewing clients. 
Initial results from NTORS show substantial improvements in all target problem 
behaviours immediately after starting treatment. Specific improvements were noted 
in the use of heroin and other illicit drugs. Reductions were also noted in injecting, 
needle sharing and criminal behaviour. 
The European and international dimensions 
Representatives from COST A-6, the Federation of European Professionals Working 
in the Field of Drug Abuse (ERIT) and the World Health Organisation (WHO) pro-
vided information on initiatives in the field of drug-abuse treatment. 
COST A-6 
Ambros Uchtenhagen, chairperson of COST A-6, detailed the aims of this pro-
gramme and, more specifically, the work of its sub-groups which have developed 
initiatives in the field of treatment evaluation. 
The main objectives of the COST A-6 programme are: 
• to set up networks of researchers at national and international level; 
• to collect, analyse and develop relevant material; and 
• to stimulate multi-centre studies related to evaluation research. 
In the area of treatment evaluation, two working groups have undertaken important 
initiatives. These groups have: 
• developed instruments for client description (EuropASI) and treatment services -
these initiatives were followed by training courses at European level and have 
also provided material for multi-centre studies; 
• reviewed the relevant evaluation studies in a number of European countries and 
the methodology and instruments used in these studies; and 
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• built up a network of scientists and professionals engaged in evaluation research 
across Europe to exchange information, organise workshops and prepare guide-
lines for treatment evaluation. 
The needs identified in the treatment-evaluation field differ according to the profes-
sional focus - researchers want outcome evaluation, practitioners want process 
evaluation, and administrators require cost-benefit analysis. Adequate instruments 
for conducting process evaluation and cost-benefit analysis for international use still 
have to be identified and developed, while guidelines for treatment evaluation wil l 
soon be defined. 
Finally, Uchtenhagen underlined the added value in the field of treatment evaluation 
of COST A-6 joining forces with the EMCDDA, so that the basic initiatives under-
taken by the group could be further developed and promoted within the REITOX 
system. 
ERIT 
Umberto Nizzoli is the President of ERIT which represents approximately 5,000 pro-
fessionals in Europe. The Federation aims to exchange information, compare experi-
ences and spread the culture of evaluation. To this end, ERIT organises seminars and 
studies the institutional and social conditions in each country in an effort to locate 
evaluation in a particular context. 
Systematic work on existing evaluation of medical, psychological and socio-
educational treatments in Europe has been supported by EU funding. Results of this 
work show that the need for evaluation is strongly felt in Europe and its practice, 
although irregular, is increasing. However, it is often carried out in limited areas and 
communication with others is lacking. ERIT has also collected instruments used for 
evaluation systematically through its network (see ERIT, 1997). 
World Health Organisation 
The WHO's work in the field of drug-treatment evaluation was presented at the 
workshop by Maristela Monteiro. A three-year project (initiated in 1996) on the 
effectiveness of drug treatment will develop, test and disseminate international 
guidelines on treatment evaluation. A training package is being prepared that wil l be 
field tested in all W H O regions. 
The report of the project's advisory group was presented by Monteiro at the work-
shop. This paper included the rationale for undertaking a proper evaluation, explor-
ing evaluation assessment, needs assessment, process evaluation, costing frame-
works, client satisfaction and outcome and economic evaluation. The report also 
included recommendations for improving, supporting and standardising treatment 
evaluations. 
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Recommendations 
The workshop identified the following priority areas in promoting the evaluation of 
treatment research in Europe: 
To improve the general methodology of evaluation studies by stimulating inter-
disciplinary collaboration. 
To develop structural and causal models for connecting theoretical constructs, 
measurement variables and results. 
To carry out meta-analyses on the growing volume of empirical results. 
To identify key variables to be used as valid evaluation criteria. 
To develop appropriate measurement instruments, especially in the areas of treat-
ment-programme and treatment-process variables. 
To promote qualitative studies. 
To promote the standardisation and adaptation of methods and instruments in 
each EU Member State. 
To improve and develop techniques for economic evaluation. 
To develop guidelines for conducting evaluation studies, including effectiveness 
and economic evaluation. 
To promote compatibility in data collection and evaluation within and between 
countries. 
To promote the dissemination of methods, instruments and evaluation results. 
To promote training in evaluation for different groups of professionals: 
practitioners (to learn the principles of empirical research, better understand 
evaluation research results and develop empirical questions that can be 
answered by empirical studies); 
managers, policy- and decision-makers (to learn how to formulate questions 
for researchers, identify which questions can be answered and which cannot, 
and learn how to understand and make use of evaluation research results); 
and 
researchers (to increase expertise in applying high-quality evaluation 
research, and improve the understanding and application of appropriate 
statistical methods for analysing evaluation data). 
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RECOMMENDATIONS 
Participants at the workshop underlined the fact that the EMCDDA is in a good 
position to encourage - through its official channels of information, dissemination 
and training - national governments and decision-makers, as well as clinicians, 
researchers and programme-managers, to develop and improve drug-treatment eval­
uation. 
The following proposals for the EMCDDA's mid-term demand-reduction work plan 
were outlined on the basis of the participants' contributions. 
Promoting existing knowledge 
1. To prepare and disseminate a short publication in all European languages 
addressed to a large audience of decision-makers and professionals. This could 
start the process of building an 'evaluation culture'. Topics could include: 
• a synthesis of the existing knowledge about treatment practice in Europe; 
• practical issues, such as the key questions that professionals and policy-makers 
need to have answered, whether these questions can currently be answered, and 
which could be answered after appropriate evaluation studies; and 
• a brief description of the EMCDDA's work in the field of treatment evaluation. 
2. To organise a conference on treatment evaluation to promote further evaluation 
methodology based on solid scientific grounds. 
3. To publish the proceedings of that conference. 
4. To create a data bank of appropriate instruments for treatment evaluation. As well 
as describing the instruments themselves, the data bank should include infor­
mation on translations into other languages, their normalisation on population 
samples in different countries, their application in different studies, their 
usefulness appraised through the experience of their application, and so on. 
5. To collect information on existing evaluation studies in Europe. 
6. To establish a committee of experts to review and evaluate existing studies in the 
field of treatment evaluation and to synthesise information on good practice. 
Promoting scientific research 
1. To develop instruments to support process evaluation and their testing in differ­
ent Member States. 
2. To initiate a number of key projects at European level to apply, on a pilot basis, 
evaluation research using a common methodological protocol and standardised 
instruments in the areas of client, programme, process and outcome assessment. 
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Promoting evaluation studies at Member State and European level 
1. To encourage governments and decision-makers to support standardised evalua-
tion and to use results from evaluation to plan treatment services. 
2. To encourage and support the co-ordination of treatment-evaluation services by 
the National Focal Point or another research institution in each Member State. 
3. To obtain ministerial support for planning a joint initiative on treatment evalua-
tion to help improve treatment provision across Member States. 
4. To develop in close collaboration with the National Focal Points a European 
policy document for the joint evaluation initiative. 
5. To organise a conference at Ministerial level to discuss and adopt the policy 
document and to specify the desired outcomes to be achieved 5-10 years after 
its adoption. 
In this way, the EMCDDA could play a leading role in monitoring the implementa-
tion of national plans, evaluating progress and disseminating results and materials. 
A common European goal for the provision of quality treatment could lead to mea-
surable improvements in the health of Europe's drug users and the population as a 
whole. 
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Since March 1997, when the seminar that forms the subject of this monograph took 
place, the EMCDDA has taken further steps in the field of treatment evaluation. The 
Centre is co-operating with the World Health Organisation (WHO) and the United 
Nations International Drug Control Programme (UNDCP) to field test and distribute a 
series of workbooks on different aspects of treatment evaluation. These aspects include: 
• needs assessment; 
• process; 
• client satisfaction; 
• outcome; and 
• economic evaluation. 
The EMCDDA is responsible for testing these workbooks within the European Union, 
while the W H O is responsible for testing them globally. The strategy includes pro-
viding direct support in the form of training and advice to selected local projects 
either interested in or already involved in treatment evaluation. The workbooks wil l 
also be distributed to a number of treatment centres that wil l constitute a control 
group. The aims of the workbooks are: 
• to elicit feed-back from all the participants, whether in the experimental or con-
trol groups; 
• to compare the results of both groups in terms of training; 
• to provide on-going advice on evaluation; and 
• to increase the number of evaluation projects sharing the know-how contained 
on the workbooks. 
A first international training workshop took place in Reggio-Emilia, Italy, in June 
1998. 
The EMCDDA is also supporting the work of the COST A-6 working group on the 
evaluation of treatment. This group is developing guidelines for the evaluation of 
treatment which the EMCDDA plans to publish and distribute. The Centre has also 
launched studies on demand-reduction activities in the criminal-justice system; 
alternative measures to prison for drug users; outreach work; and substitution treat-
ment. These overviews pay special attention to current evaluation projects and look 
forward to establishing criteria for evaluating different types of demand-reduction 
intervention. 
Together with the National Focal Points of the REITOX network, and co-ordinated 
by Greece, the EMCDDA has been developing an instrument to describe the char-
acteristics of treatment services for implementation at EU level. This instrument is 
the Treatment Unit Form or TUF. Regarding the collection and dissemination of 
evaluation instruments, the Centre is creating an Internet-based Evaluation 
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Instrument Bank to facilitate access to evaluation tools in the field of demand 
reduction and to provide interested clinical and scientific networks with the latest 
developments in evaluation. 
The EMCDDA has played a major role in facilitating information exchange in the 
areas covered by the above projects, as well as in other domains in which it may 
become involved in the future. The Centre's main goals have been to help improve 
the policies and practice of assistance to drug users by promoting a culture of eval-
uation. To this end, new information technology, above all Internet and e-mail, have 
proved particularly valuable for the EMCDDA's work. 
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